



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12Q 1/68	A1	(11) International Publication Number: WO 00/24936 (43) International Publication Date: 04 May 2000 (04.05.2000)
---	-----------	--

(21) International Application Number: PCT/US99/25025
(22) International Filing Date: 27 October 1999 (27.10.1999)

Published

(30) Priority Data:
09/179,569 27 October 1998 (27.10.1998) US
09/220,275 23 December 1998 (23.12.1998) US

(60) Parent Application or Grant
ROSETTA INPHARMATICS, INC. [/]; (). FRIEND, Stephen,
H. [/]; (). STOUGHTON, Roland [/]; (). HE, Yudong [/];
(). FRIEND, Stephen, H. [/]; (). STOUGHTON, Roland [/];
(). HE, Yudong [/]; (). ANTILER, Adriane, M. ; ().

(54) Title: METHODS FOR USING CO-REGULATED GENESETS TO ENHANCE DETECTION AND CLASSIFICATION OF GENE EXPRESSION PATTERNS

(54) Titre: PROCÉDES POUR UTILISER DES ENSEMBLES GENIQUES CO-REGULÉS AFIN D'AMÉLIORER LA DÉTECTION ET LA CLASSIFICATION DE MODÈLES D'EXPRESSION GENIQUE

(57) Abstract

The present invention provides methods for enhanced detection of biological response patterns. In one embodiment of the invention, genes are grouped into basis genesets according to the co-regulation of their expression. Expression of individual genes within a geneset is indicated with a single gene expression value for the geneset by a projection process. The expression values of genesets, rather than the expression of individual genes, are then used as the basis for comparison and detection of biological response with greatly enhanced sensitivity. In another embodiment of the invention, biological responses are grouped according to the similarity of their biological profile. The methods of the invention have many useful applications, particularly in the fields of drug development and discovery. For example, the methods of the invention may be used to compare biological responses with greatly enhanced sensitivity. The biological responses that may be compared according to these methods include responses to single perturbations, such as a biological response to a mutation or temperature change, as well as graded perturbations such as titration with a particular drug. The methods are also useful to identify cellular constituents, particularly genes, associated with a particular type of biological response. Further, the methods may also be used to identify perturbations, such as novel drugs or mutations, which effect one or more particular genesets. The methods may still further be used to remove experimental artifacts in biological response data.

(57) Abrégé

La présente invention concerne des procédés permettant une meilleure détection de modèles de réaction biologique. Dans un mode de réalisation de l'invention, les gènes sont regroupés en des ensemble géniques ("genesets") de base en fonction de la co-régulation de leur expression. L'expression de gènes individuels à l'intérieur d'un "geneset" donné est indiquée sur la base de la valeur d'expression d'un gène unique pour le geneset, au moyen d'un processus de projection. On utilise ensuite les valeurs d'expression des "genesets" plutôt que celles de gènes individuels à des fins de comparaison et de détection de réaction biologique, et ce avec un degré de sensibilité sensiblement plus élevé. Dans un autre mode de réalisation de l'invention, les réactions biologiques sont regroupées en fonction de la similitude de leur profil biologique. Les procédés de l'invention ont de nombreuses applications pratiques, notamment dans le domaine de développement et de découverte de médicaments. Ainsi, les procédés de l'invention peuvent être utilisés pour comparer les réactions biologiques avec une sensibilité beaucoup plus élevée. Les réactions biologiques qui peuvent être comparées selon ces procédés comprennent les réactions à des perturbations isolées, par exemple, à une mutation ou à un changement de température, ou à des perturbations graduées telles que le titrage avec un médicament déterminé. Les procédés peuvent aussi servir à identifier des éléments constitutifs cellulaires, notamment des gènes, associés à un type déterminé de réponse biologique. En outre, ces procédés peuvent aussi servir à identifier des perturbations causées par de nouveaux médicaments ou par des mutations, provoquées par un ou plusieurs "genesets" donnés. Les procédés peuvent aussi servir à évacuer des artefacts expérimentaux contenus dans des données relatives à des réactions biologiques.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/24936 (43) International Publication Date: 4 May 2000 (04.05.00)
<p>(21) International Application Number: PCT/US99/25025</p> <p>(22) International Filing Date: 27 October 1999 (27.10.99)</p> <p>(30) Priority Data: 09/179,569 27 October 1998 (27.10.98) US 09/220,275 23 December 1998 (23.12.98) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/220,275 (CIP) Filed on 23 December 1998 (23.12.98)</p> <p>(71) Applicant (for all designated States except US): ROSETTA INPHARMATICS, INC. [US/US]; 12040 115th Avenue, N.E., Kirkland, WA 98034 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): FRIEND, Stephen, H. [US/US]; 2653 Cascade Avenue S., Seattle, WA 98144 (US). STOUGHTON, Roland [US/US]; 425 West Spruce Street, San Diego, CA 92103 (US). HE, Yudong [CN/US]; 11410 N.E. 124th Street #148, Kirkland, WA 98034 (US).</p>		<p>(74) Agents: ANTLER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: METHODS FOR USING CO-REGULATED GENESETS TO ENHANCE DETECTION AND CLASSIFICATION OF GENE EXPRESSION PATTERNS</p> <p>(57) Abstract</p> <p>The present invention provides methods for enhanced detection of biological response patterns. In one embodiment of the invention, genes are grouped into basis genesets according to the co-regulation of their expression. Expression of individual genes within a geneset is indicated with a single gene expression value for the geneset by a projection process. The expression values of genesets, rather than the expression of individual genes, are then used as the basis for comparison and detection of biological response with greatly enhanced sensitivity. In another embodiment of the invention, biological responses are grouped according to the similarity of their biological profile. The methods of the invention have many useful applications, particularly in the fields of drug development and discovery. For example, the methods of the invention may be used to compare biological responses with greatly enhanced sensitivity. The biological responses that may be compared according to these methods include responses to single perturbations, such as a biological response to a mutation or temperature change, as well as graded perturbations such as titration with a particular drug. The methods are also useful to identify cellular constituents, particularly genes, associated with a particular type of biological response. Further, the methods may also be used to identify perturbations, such as novel drugs or mutations, which effect one or more particular genesets. The methods may still further be used to remove experimental artifacts in biological response data.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5

**METHODS FOR USING CO-REGULATED GENESETS TO ENHANCE
DETECTION AND CLASSIFICATION OF GENE EXPRESSION PATTERNS**

10 This is a continuation-in-part of application serial no. 09/220,275, filed on
5 December 23, 1998, which is a continuation-in-part of application serial no. 09/179,569
filed October 27, 1998, each of which is incorporated herein, by reference, in its entirety.

15

1. FIELD OF THE INVENTION

The field of this invention relates to methods for enhanced detection of biological
10 responses to perturbations. In particular, it relates to methods for analyzing structure in
biological expression patterns for the purposes of improving the ability to detect certain
specific gene regulations and to classify more accurately the actions of compounds that
20 produce complex patterns of gene regulation in the cell.

15

2. BACKGROUND OF THE INVENTION

25 Within the past decade, several technologies have made it possible to monitor the
expression level of a large number of transcripts at any one time (*see, e.g.*, Schena *et al.*,
1995, Quantitative monitoring of gene expression patterns with a complementary DNA
micro-array, *Science* 270:467-470; Lockhart *et al.*, 1996, Expression monitoring by
20 hybridization to high-density oligonucleotide arrays, *Nature Biotechnology* 14:1675-1680;
Blanchard *et al.*, 1996, Sequence to array: Probing the genome's secrets, *Nature
Biotechnology* 14, 1649; U.S. Patent 5,569,588, issued October 29, 1996 to Ashby *et al.*
entitled "Methods for Drug Screening"). In organisms for which the complete genome is
35 known, it is possible to analyze the transcripts of all genes within the cell. With other
25 organisms, such as human, for which there is an increasing knowledge of the genome, it is
possible to simultaneously monitor large numbers of the genes within the cell.

Such monitoring technologies have been applied to the identification of genes which
40 are up regulated or down regulated in various diseased or physiological states, the analyses
of members of signaling cellular states, and the identification of targets for various drugs.
30 *See, e.g.*, Friend and Hartwell, U.S. Provisional Patent Application Serial No. 60/039,134,
filed on February 28, 1997; Stoughton, U.S. Patent Application Serial No. 09/099,722, filed
on June 19, 1998; Stoughton and Friend, U.S. Patent Application Serial No. 09/074,983,
45 filed on May 8, 1998; Friend and Hartwell, U.S. Provisional Application Serial No.
60/056,109, filed on August 20, 1997; Friend and Hartwell, U.S. Application Serial No.
35 09/031,216, filed on February 26, 1998; Friend and Stoughton, U.S. Provisional
Application Serial Nos. 60/084,742 (filed on May 8, 1998), 60/090,004 (filed on June 19,

1998) and 60/090,046 (filed on June 19, 1998), all incorporated herein by reference for all purposes.

Levels of various constituents of a cell are known to change in response to drug treatments and other perturbations of the cell's biological state. Measurements of a plurality of such "cellular constituents" therefore contain a wealth of information about the effect of perturbations and their effect on the cell's biological state. Such measurements typically comprise measurements of gene expression levels of the type discussed above, but may also include levels of other cellular components such as, but by no means limited to, levels of protein abundances, or protein activity levels. The collection of such measurements is generally referred to as the "profile" of the cell's biological state.

The number of cellular constituents is typically on the order of a hundred thousand for mammalian cells. The profile of a particular cell is therefore typically of high complexity. Any one perturbing agent may cause a small or a large number of cellular constituents to change their abundances or activity levels. Not knowing what to expect in response to any given perturbation will therefore require measuring independently the responses of these about 10^5 constituents if the action of the perturbation is to be completely or at least mostly characterized. The complexity of the biological response data coupled with measurement errors makes such an analysis of biological response data a challenging task.

Current techniques for quantifying profile changes suffer from high rates of measurement error such as false detection, failures to detect, or inaccurate quantitative determinations. Therefore, there is a great demand in the art for methods to enhance the detection of structure in biological expression patterns. In particular, there is a need to find groups and structure in sets of measurements of cellular constituents, e.g., in the profile of a cell's biological state. Examples of such structure include associations between the regulation of the expression levels of different genes, associations between different drug or drug candidates, and association between the drugs and the regulation of sets of genes.

Discussion or citation of a reference herein shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION

This invention provides methods for enhancing detection of structures in the response of biological systems to various perturbations, such as the response to a drug, a drug candidate or an experimental condition designed to probe biological pathways as well as changes in biological systems that correspond to a particular disease or disease state, or

5 to a treatment of a particular disease or disease state. The methods of this invention have
extensive applications in the areas of drug discovery, drug therapy monitoring, genetic
analysis, and clinical diagnosis. This invention also provides apparatus and computer
instructions for performing the enhanced detection of biological response patterns, drug
10 discovery, monitoring of drug therapies, genetic analysis, and clinical diagnosis.

One aspect of the invention provides methods for classifying cellular constituents
(measurable biological variables, such as gene transcripts and protein activities) into groups
based upon the co-variation among those cellular constituents. Each of the groups
15 has cellular constituents that co-vary in response to perturbations. Those groups are termed
cellular constituent sets.

In some specific embodiments, genes are grouped according to the degree of co-
variation of their transcription, presumably co-regulation. Groups of genes that have co-
varying transcripts are termed genesets. Cluster analysis or other statistical classification
methods are used to analyze the co-variation of transcription of genes in response to a
20 variety of perturbations. In preferred embodiments, the cluster analysis or other statistical
classification methods use a novel "distance" or "similarity" metric to evaluate the
similarity (*i.e.*, the co-variance) of two or more genes (or other cellular constituents) in
response to the variety of perturbations. In one specific embodiment, clustering algorithms
are applied to expression profiles (*e.g.*, a collection of transcription rates of a number of
25 genes) obtained under a variety of cellular perturbations to construct a "similarity tree" or
"clustering tree" which relates cellular constituents by the amount of co-regulation
exhibited. Genesets are defined on the branches of a clustering tree by cutting across the
clustering tree at different levels in the branching hierarchy. In some embodiments, the
cutting level is chosen based upon the number of distinct response pathways expected for
30 the genes measured. In some other embodiments, the tree is divided into as many branches
as they are truly distinct in terms of minimal distance value between the individual
branches.

In some preferred embodiments, objective statistical tests are employed to define
truly distinct branches. One exemplary embodiment of such a statistical test employs
30 Monte Carlo randomization of the perturbation index for each gene's responses across all
perturbations tested. In some preferred embodiments, the cut off level is set so that
branching is significant at the 95% confidence level. In preferred embodiments, clusters
with one or two genes are discarded. In some other embodiments, however, small clusters
with one or two genes are included in genesets. In more detail, the preferred statistical tests
35 of the invention comprise (a) obtaining a measure of the "compactness" of clusters (*i.e.*,
cellular constituent sets such as gene sets) determined by the above mentioned cluster

5 analysis or other statistical techniques, and (b) comparing the thus obtained measure of compactness to a hypothetical measure of compactness of cellular constituents regrouped in an increased number of clusters. Such a comparison typically comprises determining the difference in the compactness of the two sets of clusters. Further, by employing Monte
10 Carlo randomization of the perturbation index for each gene's responses across all perturbations tested, a statistical distribution of the difference in the compactness is thus generated. The statistical significance of the actual difference in compactness can then be determined by comparing this actual difference in compactness to the statistical distribution of the differences in compactness from the Monte Carlo randomizations.

15 As the diversity of perturbations in the clustering set becomes very large, the genesets which are clearly distinguishable get smaller and more numerous. However, it is a discovery of the inventors that even over very large experiment sets, there is a number of genesets that retain their coherence. These genesets are termed irreducible genesets. In some embodiments of the invention, a large number of diverse perturbations are applied to
20 obtain these irreducible genesets.

25 Statistically derived genesets may be refined using regulatory sequence information to confirm members that are co-regulated, or to identify more tightly co-regulated subgroups. In such embodiments, genesets may be defined by their response pattern to individual biological experimental perturbations such as specific mutations, or specific
30 growth conditions, or specific compounds. The statistically derived genesets may be further refined based upon biological understanding of gene regulation. In another preferred embodiment, classification of genes into genesets is based first upon the known regulatory mechanisms of genes. Sequence homology of regulatory regions is used to define the genesets. In some embodiments, genes with common promoter sequences are grouped into
35 one geneset.

40 In preferred embodiments, the cluster analysis and statistical classification methods of this invention analyze co-variation, *e.g.*, of transcription levels of individual genes, by means of an objective, quantitative "similarity" or "distance" function which provides a useful measurement of the similarity of expression levels for two or more cellular
30 constituents (*e.g.*, for two or more genes). Accordingly, the present invention provides novel similarity or distance function which are particularly useful for analyzing the co-variation of cellular constituents, including the co-variation of gene transcript levels. The invention also provides objective statistical tests, in particular Monte Carlo procedures, for assessing the significance of the cellular constituent sets or genesets obtained by the
45 methods of this invention. Finally, the clustering methods of this invention are equally applicable to the clustering of both cellular constituents and biological profiles according to
50

5 their similarities. Thus, in another aspect, the present invention provides methods for simultaneous clustering in both dimension of a tabular data set. In preferred embodiments, the data set is a table of numbers representing the levels or changes in level, of a plurality of cellular constituents in response to different conditions, perturbations, or conditions
10 pairs.

Another aspect of the invention provides methods for expressing the state (or biological responses) of a biological sample on the basis of co-varying cellular constituent sets. In some embodiments, a profile containing a plurality of measurements of cellular constituents in a biological sample is converted into a projected profile containing a
15 plurality of cellular constituent set values according to a definition of co-varying basis cellular constituent sets. In some preferred embodiments, the cellular constituent set values are the average of the cellular constituent values within a cellular constituent set. In some other embodiments, the cellular constituent set values are derived from a linear projection process. The projection operation expresses the profile on a smaller and biologically more
20 meaningful set of coordinates, reducing the effects of measurement errors by averaging them over each cellular constituent sets, and aiding biological interpretation of the profile.

The method of the invention is particularly useful for the analysis of gene expression profiles. In some embodiments, a gene expression profile, such as a collection of transcription rates of a number of genes, is converted to a projected gene expression profile.
25 The projected gene expression profile is a collection of geneset expression values. The conversion is achieved, in some embodiments, by averaging the transcription rate of the genes within each geneset. In some other embodiments, other linear projection processes may be used.

In yet another aspect of the invention, methods for comparing cellular constituent set
35 values, particularly, geneset expression values are provided. In some embodiments, the expression of at least 10, preferably more than 100, more preferably more than 1,000 genes of a biological system is monitored. A known drug is applied to the system to generate a known drug response profile in terms of genesets. A drug candidate is also applied to the
40 biological system to obtain a drug candidate response profile in terms of genesets. The drug candidate's response profile is then compared with the known drug response profile to determine whether the drug candidate induces a response similar to the response to a known drug.

In some other embodiments, the comparison of projected profiles is achieved by using an objective measure of similarity. In some preferred embodiments, the objective
35 measure is the generalized angle between the vectors representing the projections of the two profiles being compared (the 'normalized dot product'). In some other embodiments, the

5 projected profiles are analyzed by applying threshold to the amplitude associated with each geneset for the projected profile. If the change of a geneset is above a threshold, it is declared that a change is present in the geneset.

10 The methods of the present invention may also be used to group biological response profiles according to the similarity of the responses of measured cellular constituents. Accordingly, in alternative embodiments, the present invention provides methods for grouping biological responses (*i.e.*, response profiles) according to the degree of similarity of the cellular constituents' responses by means of the cluster analysis or other statistical classification methods described *supra* for classification of cellular constituents (*e.g.*, genes) 15 into co-varying sets (*e.g.*, genesets). Such methods may also be used, *e.g.*, for enhancing detection of structures in the responses of biological systems to various perturbations. Still further, the present invention also provides "two-dimensional" methods of analyzing biological response profile data. Such methods simply comprise (1) grouping cellular constituents (*e.g.*, genes) according to their degree of co-variation in the response profile 20 data, and (2) grouping response profiles according to the similarity of their cellular constituents' responses.

25 The clustering methods of the invention are particularly useful, *e.g.*, for identifying and/or characterizing perturbations (for example, drugs, drug candidates or genetic mutations) affecting particular cellular constituents or particular groups of cellular constituents. For example, the clustering methods can be used to identify cellular constituents (*e.g.*, genes and proteins) and/or sets of co-varying cellular constituents such as genesets whose changes in expression or abundance are associated with a particular biological effect such as a particular disease state or the effect of one or more drugs. 30 Further, the clustering methods of the invention are also useful, *e.g.*, for identifying cellular constituents, such as genes or gene transcripts, involved in a particular biological response or pathway. Thus, the invention further provides methods for identifying cellular constituents, such as genes or gene transcripts, associated with a particular biological response or pathway by means of the cluster analysis methods described *supra*. The invention still further provides methods for identifying biological "perturbations", for 35 example drugs, drug candidates, or genetic mutations which "perturb" a biological system, effecting particular cellular constituents or particular groups of cellular constituents by means of the cluster analysis methods described *supra*. The cellular constituents and perturbations identified by the methods of the invention may be known or previously unknown. Thus, the invention provides methods for identifying, *e.g.*, novel genes and 40 drugs or drug candidates as well previously known genes and drugs/drug candidates which were not previously known to be associated with a particular biological effect of interest.

5 The methods of the present invention may also be used to remove one or more artifacts from a measured biological profile (*i.e.*, from a measure profile comprising a plurality of measurements of cellular constituents). Thus, the invention provides methods for removing such artifacts from a measured biological profile by subtracting one or more artifact patterns from the measured biological profile, wherein each artifact pattern corresponds to a particular artifact.

15 The methods of the invention are preferably implemented with a computer system capable of executing cluster analysis and projection operations. In some embodiments, a computer system contains a computer-usable medium having computer readable program code embodied. The computer code is used to effect retrieving a definition of basis genesets from a database and converting a gene expression profile into a projected expression profile according to the retrieved definition.

15 4. BRIEF DESCRIPTION OF THE DRAWINGS

25 Fig. 1 illustrates an embodiment of the cluster analysis.

Fig. 2 illustrates the projection process.

30 Fig. 3 illustrates an exemplary geneset database management system.

Fig. 4A illustrates two different possible responses to receptor activation.

35 Fig. 4B illustrates three main clusters of yeast genes with distinct temporal behavior.

Fig. 5 illustrates a computer system useful for embodiments of the invention.

40 Fig. 6 shows a clustering tree derived from 'hclust' algorithm operating on a table of 18 experiments by 48 mRNA levels.

45 Fig. 7 shows a clustering tree derived from 34 experiments.

Fig. 8A-E shows amplitudes of the individual elements of the projected profile.

Fig. 9 shows results of correlating the profile of FK506 (16 $\mu\text{g/ml}$) treatment with the profiles of each of the 34 experiments used to generate the basis genesets.

Fig. 10 illustrates an exemplary signaling cascade which includes a group of up-regulated genes (*G1*, *G2*, and *G3*) and a group of down regulated genes (*G4*, *G5*, and *G6*).

Fig. 11 is the clustering tree obtained by the *hclust* algorithm to identify clusters (i.e., genesets) among 185 genes whose expression levels were measured in 34 perturbation response profiles.

Fig. 12 illustrates an exemplary, two-dimensional embodiment of the Monte Carlo method for assigning significance to cluster subdivisions.

Fig. 13 shows the transcriptional response of the largest responding genes of *S. cerevisiae* to different concentrations of the drug FK506.

Fig. 14 shows projected titration curves obtained by projecting the titration curves of Fig. 13.

Fig. 15 is chi-squared plotted around the values of the two Hill coefficients n and u_0 derived for each geneset in Fig. 14.

Fig. 16A-D illustrates an exemplary application of the methods of the invention; Fig. 16A is a grey scale display of 185 genetic transcripts of *S. Cerevisiae* (horizontal axis) measured in 34 different perturbation experiments (vertical axis); Fig. 16B shows the co-regulation tree obtained by clustering the genetic transcripts of Fig. 16A using the 'hclust' algorithm; Fig. 16C is an illustration of the same experimental data in which the transcripts (horizontal axis) have been re-ordered according to the genesets defined from Fig. 16B; Fig. 16D is another illustration of the experimental data in which the experimental index (vertical axis) has also been reordered according to similarity of the response profiles.

Fig. 17 is another illustration of the data in Fig. 16 in which the genetic transcripts (horizontal axis) and experiments (vertical axis) are ordered according to similarity; individual genesets are identified above the false color image, while the biological pathways and/or responses with which each geneset is associated are indicated below the image; the label on the vertical axis summarizes each experiment.

Fig. 18 shows the correlation of the expression profiles of a (believed to be) uncontaminated experiment measuring the effect of deletion of the gene YJL107c in *S. cerevisiae* and an identical experiment unintentionally contaminated with an artifact (poor control of RNA concentration during reverse transcription).

Fig. 19 shows a profile, plotted as gene expression ratio vs. mean expression level, corresponding to poor control of RNA concentration in a reverse transcription procedure during hybridization sample preparation.

Fig. 20 shows the correlation of the expression profile of a (believed to be) uncontaminated experiment measuring the effect of deletion of the gene YJL107c in *S. cerevisiae* and an identical experiment unintentionally contaminated with an artifact (poor control of RNA concentration during reverse transcription) wherein the data from the contaminated has been "cleaned" using the response profile in Fig. 19 as a "template" of the artifact.

5. DETAILED DESCRIPTION

This section presents a detailed description of the invention and its applications. This description is by way of several exemplary illustrations, in increasing detail and specificity, of the general methods of this invention. These examples are non-limiting, and related variants will be apparent to one of skill in the art.

Although, for simplicity, this disclosure often makes references to gene expression profiles, transcriptional rate, transcript levels, etc., it will be understood by those skilled in the art that the methods of the inventions are useful for the analysis of any biological response profile. In particular, one skilled in the art will recognize that the methods of the present invention are equally applicable to biological profiles which comprise measurements of other cellular constituents such as, but not limited to, measurements of protein abundance or protein activity levels.

5.1. INTRODUCTION

The state of a cell or other biological sample is represented by cellular constituents (any measurable biological variables) as defined in Section 5.1.1, *infra*. Those cellular constituents vary in response to perturbations. A group of cellular constituents may co-vary in response to particular perturbations. Accordingly, one aspect of the present invention provides methods for grouping co-varying cellular constituents. Each group of co-varying cellular constituents is termed a cellular constituent set. This invention is partially premised

5 upon a discovery of the inventors that the state of a biological sample can be more
advantageously represented using cellular constituent sets rather than individual cellular
constituents. It is also a discovery of the inventors that the response of a biological sample
10 can be better analyzed in terms of responses of co-varying cellular constituent sets rather
5 than cellular constituents.

In some preferred specific embodiments of this invention, genes are grouped into
basis genesets according to the regulation of their expression. Transcriptional rates of
individual genes within a geneset are combined to obtain a single gene expression value for
15 the geneset by a projection process. The expression values of genesets, rather than the
transcriptional rate of individual genes, are then used as the basis for the comparison and
10 detection of biological responses with greatly enhanced sensitivity.

This section first presents a background about representations of biological state and
biological responses in terms of cellular constituents. Next, a schematic and non-limiting
overview of the invention is presented, and the representation of biological states and
15 biological responses according to the method of this invention is introduced. The following
sections present specific non-limiting embodiments of this invention in greater detail.

5.1.1. DEFINITION OF BIOLOGICAL STATE

As used in herein, the term "biological sample" is broadly defined to include any
20 cell, tissue, organ or multicellular organism. A biological sample can be derived, for
example, from cell or tissue cultures *in vitro*. Alternatively, a biological sample can be
derived from a living organism or from a population of single cell organisms.

The state of a biological sample can be measured by the content, activities or
structures of its cellular constituents. The state of a biological sample, as used herein, is
35 taken from the state of a collection of cellular constituents, which are sufficient to
characterize the cell or organism for an intended purpose including, but not limited to
characterizing the effects of a drug or other perturbation. The term "cellular constituent" is
also broadly defined in this disclosure to encompass any kind of measurable biological
variable. The measurements and/or observations made on the state of these constituents can
40 be of their abundances (*i.e.*, amounts or concentrations in a biological sample), or their
activities, or their states of modification (*e.g.*, phosphorylation), or other measurements
relevant to the biology of a biological sample. In various embodiments, this invention
includes making such measurements and/or observations on different collections of cellular
45 constituents. These different collections of cellular constituents are also called herein
35 aspects of the biological state of a biological sample.

5 One aspect of the biological state of a biological sample (*e.g.*, a cell or cell culture) usefully measured in the present invention is its transcriptional state. In fact, the transcriptional state is the currently preferred aspect of the biological state measured in this invention. The transcriptional state of a biological sample includes the identities and
10 abundances of the constituent RNA species, especially mRNAs, in the cell under a given set of conditions. Preferably, a substantial fraction of all constituent RNA species in the biological sample are measured, but at least a sufficient fraction is measured to characterize the action of a drug or other perturbation of interest. The transcriptional state of a
15 biological sample can be conveniently determined by, *e.g.*, measuring cDNA abundances by any of several existing gene expression technologies. One particularly preferred embodiment of the invention employs DNA arrays for measuring mRNA or transcript level
20 of a large number of genes.

Another aspect of the biological state of a biological sample usefully measured in the present invention is its translational state. The translational state of a biological sample
15 includes the identities and abundances of the constituent protein species in the biological sample under a given set of conditions. Preferably, a substantial fraction of all constituent protein species in the biological sample is measured, but at least a sufficient fraction is measured to characterize the action of a drug of interest. As is known to those of skill in the art, the transcriptional state is often representative of the translational state.

20 Other aspects of the biological state of a biological sample are also of use in this invention. For example, the activity state of a biological sample, as that term is used herein, includes the activities of the constituent protein species (and also optionally catalytically active nucleic acid species) in the biological sample under a given set of conditions. As is
30 known to those of skill in the art, the translational state is often representative of the activity state.
35

This invention is also adaptable, where relevant, to "mixed" aspects of the biological state of a biological sample in which measurements of different aspects of the biological state of a biological sample are combined. For example, in one mixed aspect, the
40 abundances of certain RNA species and of certain protein species, are combined with measurements of the activities of certain other protein species. Further, it will be appreciated from the following that this invention is also adaptable to other aspects of the biological state of the biological sample that are measurable.
45

The biological state of a biological sample (*e.g.*, a cell or cell culture) is represented by a profile of some number of cellular constituents. Such a profile of cellular constituents
35 can be represented by the vector \mathcal{S} .

$$S = [S_1, \dots, S_i, \dots, S_k] \quad (1)$$

Where S_i is the level of the i 'th cellular constituent, for example, the transcript level of gene i , or alternatively, the abundance or activity level of protein i .

In some embodiments, cellular constituents are measured as continuous variables. For example, transcriptional rates are typically measured as number of molecules synthesized per unit of time. Transcriptional rate may also be measured as percentage of a control rate. However, in some other embodiments, cellular constituents may be measured as categorical variables. For example, transcriptional rates may be measured as either "on" or "off", where the value "on" indicates a transcriptional rate above a predetermined threshold and value "off" indicates a transcriptional rate below that threshold.

5.1.2. REPRESENTATION OF BIOLOGICAL RESPONSES

The responses of a biological sample to a perturbation, such as the application of a drug, can be measured by observing the changes in the biological state of the biological sample. A response profile is a collection of changes of cellular constituents. In the present invention, the response profile of a biological sample (e.g., a cell or cell culture) to the perturbation m is defined as the vector $v^{(m)}$:

$$v^{(m)} = [v_1^{(m)}, \dots, v_i^{(m)}, \dots, v_k^{(m)}] \quad (2)$$

Where $v_i^{(m)}$ is the amplitude of response of cellular constituent i under the perturbation m . In some particularly preferred embodiments of this invention, the biological response to the application of a drug, a drug candidate or any other perturbation, is measured by the induced change in the transcript level of at least 2 genes, preferably more than 10 genes, more preferably more than 100 genes and most preferably more than 1,000 genes.

In some embodiments of the invention, the response is simply the difference between biological variables before and after perturbation. In some preferred embodiments, the response is defined as the ratio of cellular constituents before and after a perturbation is applied. In other embodiments, the response may be a function of time after the perturbation, i.e., $v^{(m)} = v^{(m)}(t)$. For example $v^{(m)}(t)$ may be the difference or ratio of cellular constituents before the perturbation and at time t after the perturbation.

In some preferred embodiments, $v_i^{(m)}$ is set to zero if the response of gene i is below some threshold amplitude or confidence level determined from knowledge of the

measurement error behavior. In such embodiments, those cellular constituents whose measured responses are lower than the threshold are given the response value of zero, whereas those cellular constituents whose measured responses are greater than the threshold retain their measured response values. This truncation of the response vector is a good strategy when most of the smaller responses are expected to be greatly dominated by measurement error. After the truncation, the response vector $v^{(m)}$ also approximates a 'matched detector' (see, e.g., Van Trees, 1968, Detection, Estimation, and Modulation Theory Vol. I, Wiley & Sons) for the existence of similar perturbations. It is apparent to those skilled in the art that the truncation levels can be set based upon the purpose of detection and the measurement errors. For example, in some embodiments, genes whose transcript level changes are lower than two fold or more preferably four fold are given the value of zero.

In some preferred embodiments, perturbations are applied at several levels of strength. For example, different amounts of a drug may be applied to a biological sample to observe its response. In such embodiments, the perturbation responses may be interpolated by approximating each by a single parameterized "model" function of the perturbation strength u . An exemplary model function appropriate for approximating transcriptional state data is the Hill function, which has adjustable parameters a , u_0 , and n .

$$H(u) = \frac{a(u/u_0)^n}{1 + (u/u_0)^n} \quad (3)$$

The adjustable parameters are selected independently for each cellular constituent of the perturbation response. Preferably, the adjustable parameters are selected for each cellular constituent so that the sum of the squares of the differences between the model function (e.g., the Hill function, Equation 3) and the corresponding experimental data at each perturbation strength is minimized. This preferable parameter adjustment method is well known in the art as a least squares fit. Other possible model functions are based on polynomial fitting, for example by various known classes of polynomials. More detailed description of model fitting and biological response has been disclosed in Friend and Stoughton, Methods of Determining Protein Activity Levels Using Gene Expression Profiles, U.S. Provisional Application Serial No. 60/084,742, filed on May 8, 1998, which is incorporated herein by reference for all purposes.

5.1.3. OVERVIEW OF THE INVENTION

This invention provides a method for enhanced detection, classification, and pattern recognition of biological states and biological responses. It is a discovery of the inventors

5 that biological state and response measurements, *i.e.*, cellular constituents and changes of cellular constituents can be classified into co-varying sets. Expressing biological states and responses in terms of those co-varying sets offers many advantages over representation of profiles of biological states and responses.

10 5 One aspect of the invention provides methods for defining co-varying cellular constituent sets. Fig. 1 is a schematic view of an exemplary embodiment of this aspect of invention. First, a biological sample (or a population of biological samples) is subject to a wide variety of perturbations (101). The biological sample may be repeatedly tested under
15 different perturbations sequentially or many biological samples may be used and each of the 10 biological samples can be tested for one perturbation. For a particular type of perturbation, such as a drug, different doses of the perturbation may be applied.

20 In some particularly preferred embodiments, different chemical compounds, mutations, temperature changes, etc., are used as perturbations to generate a large data set. In most embodiments, at least 5, preferably more than 10, more preferably more than 50,
25 most preferably more than 100 different perturbations are employed.

30 In the preferred embodiment of the invention, the biological samples used here for cluster analysis are of the same type and from the same species as the species of interest. For example, human kidney cells are tested to define cellular constituent sets that are useful for the analysis of human kidney cells. In some other preferred embodiments, the biological
35 samples used here for cluster analysis are not of the same type or not from the same species. For example, yeast cells may be used to define certain yeast cellular constituent sets that are useful for human tissue analysis.

40 The biological samples subjected to perturbation are monitored for their cellular constituents (level, activity, or structure change, etc.) (102). Those biological samples are
45 occasionally referred to herein as training samples and the data obtained are referred to as training data. The term "monitoring" as used herein is intended to include continuous measuring as well as end point measurement. In some embodiments, the cellular constituents of the biological samples are measured continuously. In other embodiments, the cellular constituents before and after perturbation are measured and compared. In still
50 other embodiments, the cellular constituents are measured in a control group of biological samples under no perturbation, and the cellular constituents of several experimental groups are measured and compared with those of the control group. It is apparent to those skilled in the art that other experimental designs are also suitable for the method of this invention to detect the change in cellular constituents in response to perturbations.

55 35 The responses of cellular constituents to various perturbations are analyzed to generate co-varying sets (103). The data are first grouped by cluster analysis according to

5 the method described in Section 5.2., *infra*, to generate a cluster tree which depicts the
similarity of the responses of cellular constituents to perturbation (104). A cut off value is
set so that the number of sets (branches) is preferably matched with the number of known
10 pathways involving the cellular constituents studied (105). In some embodiments where the
5 number of pathways is unknown, cellular constituents are clustered into the maximal
number of truly distinct branches (or sets).

The cellular constituent sets may be refined by utilizing the ever increasing
15 knowledge about biological pathways and regulatory pathways obtained from the art (106).
Conversely, the cluster analysis method of the invention is useful for deciphering complex
10 biological pathways.

In another aspect of the invention, biological state and biological responses of a
biological sample are represented by combined values for cellular constituent sets. In one
20 exemplary embodiment as depicted in Fig. 2, the cellular constituents (202) of a biological
sample (201) are grouped into three predefined cellular constituent sets (203), (204) and
15 (205). The measurements of the cellular constituents (202) within a cellular constituent set
are combined to generate set values (206), (207) and (208). This step of converting from
25 cellular constituent values to set values is termed 'projection.' This projection operation
expresses the profile on a smaller and biologically more meaningful set of coordinates,
reducing the effects of measurement errors by averaging them over each set, and aiding
20 biological interpretation of the profile.

Using set values does not necessarily cause loss of information by combining
individual cellular constituent values. Because the cellular constituents within a set co-
vary, individual cellular constituents provides little more information than the combined set
35 value. In most embodiments, in this step, the quantitative description of a profile changes
25 from a list of, for example, 100 numbers to a substantially shorter list, for example 10,
representing the amplitude of each individual response pattern (coordinated change in any
one geneset) needed to closely represent, in a sum, the entire profile.

The conversion of cellular constituent values into set values, however, offers many
40 benefits by greatly reducing the measurement errors and random variations and thus
30 enhancing pattern detection.

Another aspect of the invention provides methods for using the simplified
45 description, or 'projection' of the profile onto cellular constituent sets in drug discovery,
diagnosis, genetic analysis and other applications. Profiles of responses expressed in terms
of cellular constituent sets, particularly genesets in some preferred embodiments, can be
35 compared with enhanced accuracy. In some embodiments of the invention, a geneset
50 response profile of a biological sample to an unknown perturbation, such as a drug

5 candidate, is compared with the geneset profiles generated with a number of known
perturbations. The biological nature, such as its pharmacological activities, of an unknown
perturbation can be determined by examining the similarity of its response profile with
10 known profiles. In some embodiments, an objective measure of similarity is used. In one
5 particularly preferred embodiment, the generalized angle between the vectors representing
the projections of the two profiles being compared (the 'normalized dot product') is the
objective measure. In some other embodiments, the amplitude associated with each geneset
for the projected profile can be masked with threshold values to declare the presence or
15 absence of a change in that geneset. This will be a more sensitive detector of changes in
10 that geneset than one based on individual cellular constituents from that geneset detected
separately. It is also a more accurate quantitative monitor of the amplitude of change in that
geneset. Thus, the presence of specific biological perturbations can be detected more
20 sensitively, and similarities between the mechanisms of action of different compounds or
perturbations discovered more efficiently.

15

25 5.2. SPECIFIC EMBODIMENT: DEFINING BASIS GENESETS

In this section, a preferred embodiment of the invention is described in detail.
While the basis genesets are used as an illustrative embodiment of the invention, it is
apparent to those skilled in the art that this invention is not limited to genesets and gene
20 expression, but is useful for analyzing many types of cellular constituents.

30 One particular aspect of the invention provides methods for clustering co-regulated
genes into genesets. This section provides a more detailed discussion of methods for
clustering co-regulated genes.

35

25 5.2.1. CO-REGULATED GENES AND GENESETS

Certain genes tend to increase or decrease their expression in groups. Genes tend to
increase or decrease their rates of transcription together when they possess similar
40 regulatory sequence patterns, *i.e.*, transcription factor binding sites. This is the mechanism
for coordinated response to particular signaling inputs (*see, e.g.*, Madhani and Fink, 1998,
30 The riddle of MAP kinase signaling specificity, Transactions in Genetics 14:151-155;
Amone and Davidson, 1997, The hardwiring of development: organization and function of
genomic regulatory systems, Development 124:1851-1864). Separate genes which make
45 different components of a necessary protein or cellular structure will tend to co-vary.
Duplicated genes (*see, e.g.*, Wagner, 1996, Genetic redundancy caused by gene duplications
35 and its evolution in networks of transcriptional regulators, Biol. Cybern. 74:557-567) will
also tend to co-vary to the extent mutations have not led to functional divergence in the

5 regulatory regions. Further, because regulatory sequences are modular (*see, e.g., Yuh et al., 1998, Genomic cis-regulatory logic: experimental and computational analysis of a sea urchin gene, Science* 279:1896-1902), the more modules two genes have in common, the
10 greater the variety of conditions under which they are expected to co-vary their transcriptional rates. Separation between modules also is an important determinant since co-activators also are involved. In summary therefore, for any finite set of conditions, it is expected that genes will not all vary independently, and that there are simplifying subsets of
15 genes and proteins that will co-vary. These co-varying sets of genes form a complete basis in the mathematical sense with which to describe all the profile changes within that finite set of conditions. One aspect of the invention classifies genes into groups of co-varying
20 genes. The analysis of the responses of these groups, or genesets, allows the increases in detection sensitivity and classification accuracy.

5.2.2. GENESET CLASSIFICATION BY CLUSTER ANALYSIS

15 For many applications of the present invention, it is desirable to find basis genesets that are co-regulated over a wide variety of conditions. This allows the method of invention to work well for a large class of profiles whose expected properties are not well
25 circumscribed. A preferred embodiment for identifying such basis genesets involves clustering algorithms (for reviews of clustering algorithms, *see, e.g., Fukunaga, 1990, Statistical Pattern Recognition*, 2nd Ed., Academic Press, San Diego; Everitt, 1974, Cluster Analysis, London: Heinemann Educ. Books; Hartigan, 1975, Clustering Algorithms, New York: Wiley; Sneath and Sokal, 1973, Numerical Taxonomy, Freeman; Anderberg, 1973, Cluster Analysis for Applications, Academic Press: New York).

35 In some embodiments employing cluster analysis, the expression of a large number of genes is monitored as biological samples are subjected to a wide variety of perturbations *see, section 5.8, infra*, for detailed discussion of perturbations useful for this invention). A table of data containing the gene expression measurements is used for cluster analysis. In
40 order to obtain basis genesets that contain genes which co-vary over a wide variety of conditions, at least 10, preferably more than 50, most preferably more than 100 perturbations or conditions are employed. Cluster analysis operates on a table of data which
30 has the dimension $m \times k$ wherein m is the total number of conditions or perturbations and k is the number of genes measured.

45 A number of clustering algorithms are useful for clustering analysis. Clustering algorithms use dissimilarities or distances between objects when forming clusters. In some
35 embodiments, the distance used is Euclidean distance in multidimensional space:

$$I(x, y) = \left\{ \sum_i (X_i - Y_i)^2 \right\}^{1/2} \quad (4)$$

where $I(x, y)$ is the distance between gene X and gene Y (or between any other cellular constituents X and Y); X_i and Y_i are gene expression response under perturbation i . The Euclidean distance may be squared to place progressively greater weight on objects that are further apart. Alternatively, the distance measure may be the Manhattan distance *e.g.*, between gene X and Y , which is provided by:

$$I(x, y) = \sum_i |X_i - Y_i| \quad (5)$$

Again, X_i and Y_i are gene expression responses under perturbation i . Some other definitions of distances are Chebychev distance, power distance, and percent disagreement. Percent disagreement, defined as $I(x, y) = (\text{number of } X_i \neq Y_i)/i$, is particularly useful for the method of this invention, if the data for the dimensions are categorical in nature. Another useful distance definition, which is particularly useful in the context of cellular response, is $I = 1 - r$, where r is the correlation coefficient between the response vectors X , Y , also called the normalized dot product $X \cdot Y / |X| |Y|$. Specifically, the dot product $X \cdot Y$ is defined by the equation:

$$X \cdot Y = \sum_i X_i \times Y_i \quad (6)$$

and $|X| = (X \cdot X)^{1/2}$, $|Y| = (Y \cdot Y)^{1/2}$.

Most preferably, the distance measure is appropriate to the biological questions being asked, *e.g.*, for identifying co-varying and/or co-regulated cellular constituents including co-varying or co-regulated genes. For example, in a particularly preferred embodiment, the distance measure $I = 1 - r$ with the correlation coefficient which comprises a weighted dot product of the genes X and Y . Specifically, in this preferred embodiment, r_{ij} is preferably defined by the equation

$$r = \frac{\sum_i \frac{X_i Y_i}{\sigma_i^{(X)} \sigma_i^{(Y)}}}{\left[\sum_i \left(\frac{X_i}{\sigma_i^{(X)}} \right)^2 \left(\frac{Y_i}{\sigma_i^{(Y)}} \right)^2 \right]^{1/2}} \quad (7)$$

where $\sigma_i^{(X)}$ and $\sigma_i^{(Y)}$ are the standard errors associated with the measurement of genes X and Y , respectively, in experiment i .

The correlation coefficients of the normal and weighted dot products above are bounded between values of +1, which indicates that the two response vectors are perfectly correlated and essentially identical, and -1, which indicates that the two response vectors are "anti-correlated" or "anti-sense" (*i.e.*, are opposites). These correlation coefficients are particularly preferable in embodiments of the invention where cellular constituent sets or clusters are sought of constituents which have responses of the same sign.

In other embodiments, it is preferable to identify cellular constituent sets or clusters which are co-regulated or involved in the same biological responses or pathways, but which comprise similar and anti-correlated responses. For example, Fig. 10 illustrates a cascade in which a signal activates a transcription factor which up-regulated several genes, identified as *G1*, *G2*, and *G3*. In the example presented in Fig. 10, the product of *G3* is a repressor element for several different genes, *e.g.*, *G4*, *G5*, and *G6*. Thus, it is preferable to be able to identify all six genes *G1 - G6* as part of the same cellular constituent set or cluster. In such embodiments, it is preferable to use the absolute value of either the normalized or weighted dot products described above, *i.e.*, $|r|$, as the correlation coefficient.

In still other embodiments, the relationships between co-regulated and/or co-varying cellular constituents (such as genes) may be even more complex, such as in instances wherein multiple biological pathways (*e.g.*, signaling pathways) converge on the same cellular constituent to produce different outcomes. In such embodiments, it is preferable to use a correlation coefficient $r = r^{(change)}$ which is capable of identifying co-varying and/or co-regulated cellular constituents irrespective of the sign. The correlation coefficient specified by Equation 8 below is particularly useful in such embodiments.

$$r = \frac{\sum_i \left| \frac{x_i}{\sigma(x)} \right| \left| \frac{y_i}{\sigma(y)} \right|}{\left[\sum_i \left(\frac{x_i}{\sigma(x)} \right)^2 \left(\frac{y_i}{\sigma(y)} \right)^2 \right]^{1/2}} \quad (8)$$

Various cluster linkage rules are useful for the methods of the invention. Single linkage, a nearest neighbor method, determines the distance between the two closest objects. By contrast, complete linkage methods determine distance by the greatest distance between any two objects in the different clusters. This method is particularly useful in cases when genes or other cellular constituents form naturally distinct "clumps." Alternatively, the unweighted pair-group average defines distance as the average distance between all pairs of objects in two different clusters. This method is also very useful for clustering genes or other cellular constituents to form naturally distinct "clumps." Finally, the

5 weighted pair-group average method may also be used. This method is the same as the
unweighted pair-group average method except that the size of the respective clusters is used
as a weight. This method is particularly useful for embodiments where the cluster size is
suspected to be greatly varied (Sneath and Sokal, 1973, Numerical taxonomy, San
10 Francisco: W. H. Freeman & Co.). Other cluster linkage rules, such as the unweighted and
weighted pair-group centroid and Ward's method are also useful for some embodiments of
the invention. See, e.g., Ward, 1963, J. Am. Stat. Assn. 58:236; Hartigan, 1975, Clustering
algorithms, New York: Wiley.

15 In one particularly preferred embodiment, the cluster analysis is performed using the
hclust routine (see, e.g., 'hclust' routine from the software package S-Plus, MathSoft, Inc.,
Cambridge, MA). An example of a clustering 'tree' output by the hclust algorithm of S-
Plus is shown in Fig. 6 (see, also, Example 1, section 6.1, *infra*). The data set in this case
20 involved 18 experiments including different drug treatments and genetic mutations related
to the yeast *S. cerevisiae* biochemical pathway homologous to immunosuppression in
humans. The set of more than 6000 measured mRNA levels was first reduced to 48 by
selecting only those genes which had a response amplitude of at least a factor of 4 in at least
25 one of the experiments. This initial downselection greatly reduces the confusing effects of
measurement errors, which dominate the small responses of most genes in most
experiments. Clustering using 'hclust' was then performed on the resulting 18 x 48 table of
30 data, yielding the clustering tree shown in Fig. 6. When the number and diversity of
experiments in the clustering set is larger, then the fraction of measured cellular constituents
with significant responses (well above the measurement error level) is also larger, and
eventually most or all of the set of cellular constituents are retained in the first down
35 selection and become represented in the clustering tree. The genesets derived from the tree
then more completely cover the set of cellular constituents.

40 As the diversity of perturbations in the clustering set becomes very large, the
genesets which are clearly distinguishable get smaller and more numerous. However, it is a
discovery of the inventors that even over very large experiment sets, there are small
genesets that retain their coherence. These genesets are termed irreducible genesets. In
30 some embodiments of the invention, a large number of diverse perturbations are applied to
obtain such irreducible genesets. For example, Geneset No.1 at the left in Figure 6 is found
also when clustering is performed on a much larger set of perturbation conditions. A data
set of 365 yeast conditions including the 18 previously mentioned was used for cluster
45 analysis. Perturbation conditions include drug treatments at different concentrations and
measured after different times of treatment, responses to genetic mutations in various genes,
50 combinations of drug treatment and mutations, and changes in growth conditions such as

temperature, density, and calcium concentration. Most of these conditions had nothing to do with the immunosuppressant drugs used in the 18-experiment set; however, the geneset retains its coherence. Genesets No. 2 and No. 3 also retain partial coherence.

Genesets may be defined based on the many smaller branches in the tree, or a small number of larger branches by cutting across the tree at different levels – see the example dashed line in Fig. 6. The choice of cut level may be made to match the number of distinct response pathways expected. If little or no prior information is available about the number of pathways, then the tree should be divided into as many branches as are truly distinct. ‘Truly distinct’ may be defined by a minimum distance value between the individual branches. In Fig. 6, this distance is the vertical coordinate of the horizontal connector joining two branches. Typical values are in the range 0.2 to 0.4 where 0 is perfect correlation and 1 is zero correlation, but may be larger for poorer quality data or fewer experiments in the training set, or smaller in the case of better data and more experiments in the training set.

Preferably, ‘truly distinct’ may be defined with an objective test of statistical significance for each bifurcation in the tree. In one aspect of the invention, the Monte Carlo randomization of the experiment index for each cellular constituent’s responses across the set of experiments is used to define an objective test.

In some embodiments, the objective test is defined in the following manner:

Let p_{ki} be the response of constituent k in experiment i . Let $\mathcal{L}(i)$ be a random permutation of the experiment index. Then for each of a large (about 100 to 1000) number of different random permutations, construct $p_{k\mathcal{L}(i)}$. For each branching in the original tree, for each permutation:

- (1) perform hierarchical clustering with the same algorithm (‘hclust’ in this case) used on the original unpermuted data;
- (2) compute fractional improvement f in the total scatter with respect to cluster centers in going from one cluster to two clusters

$$f = 1 - \sum D_k^{(1)} / \sum D_k^{(2)} \quad (9)$$

where D_k is the square of the distance measure for constituent k with respect to the center (mean) of its assigned cluster. Superscript 1 or 2 indicates whether it is with respect to the center of the entire branch or with respect to the center of the appropriate cluster out of the two subclusters. There is considerable freedom in the definition of the distance function D used in the clustering procedure. In these examples, $D = 1 - r$, where r is the correlation

5 coefficient between the responses of one constituent across the experiment set vs. the responses of the other (or vs. the mean cluster response).

10 The distribution of fractional improvements obtained from the Monte Carlo procedure is an estimate of the distribution under the null hypothesis that particular branching was not significant. The actual fractional improvement for that branching with the unpermuted data is then compared to the cumulative probability distribution from the null hypothesis to assign significance. Standard deviations are derived by fitting a log normal model for the null hypothesis distribution.

15 The numbers displayed at the bifurcations in Fig. 6 are the significance, in standard deviations, of each bifurcation. Numbers greater than about 2, for example, indicate that the branching is significant at the 95% confidence level.

20 If, for example, the horizontal cut shown in Fig. 6 is used, and only those branches with more than two members below the cut are accepted as genesets, three genesets are obtained in Fig. 6. These three genesets reflect the pathways involving the calcineurin protein, the PDR gene, and the Gcn4 transcription factor. Therefore, genesets defined by cluster analysis have underlying biological significance.

25 In more detail, an objective statistical test is preferably employed to determine the statistical reliability of the grouping decisions of any clustering method or algorithm. Preferably, a similar test is used for both hierarchical and non-hierarchical clustering methods. More preferably, the statistical test employed comprises (a) obtaining a measure of the compactness of the clusters determined by one of the clustering methods of this invention, and (b) comparing the obtained measure of compactness to a hypothetical measure of compactness of cellular constituents regrouped in an increased number of clusters. For example, in embodiments wherein hierarchical clustering algorithms, such as *hclust*, are employed, such a hypothetical measure of compactness preferably comprises the measure of compactness for clusters selected at the next lowest branch in a clustering tree (e.g., at LEVEL 1 rather than at LEVEL 2 in Fig. 11). Alternatively, in embodiments wherein non-hierarchical clustering methods or algorithms are employed, e.g., to generate *N* clusters, the hypothetical measure of compactness is preferably the compactness obtained for *N*+1 clusters by the same methods.

30 Cluster compactness may be quantitatively defined, e.g., as the mean squared distance of elements of the cluster from the "cluster mean," or, more preferably, as the inverse of the mean squared distance of elements from the cluster mean. The cluster mean of a particular cluster is generally defined as the mean of the response vectors of all elements in the cluster. However, in certain embodiments, e.g., wherein the absolute value

of the normalized or weighted dot product is used to evaluate the distance metric (*i.e.*, $I = 1 - |r|$) of the clustering algorithm, such a definition of cluster mean is problematic. More generally, the above definition of mean is problematic in embodiments wherein response vectors may be in opposite directions such that the above defined cluster mean could be zero. Accordingly, in such embodiments, it is preferable to choose a different definition of cluster compactness, such as, but not limited to, the mean squared distance between all pairs of elements in the cluster. Alternatively, the cluster compactness may be defined to comprise the average distance (or more preferably the inverse of the average distance) from each element (*e.g.*, cellular constituent) of the cluster to all other elements in that cluster.

Preferably, Step (b) above of comparing cluster compactness to a hypothetical compactness comprises generating a non-parametric statistical distribution for the changed compactness in an increased number of clusters. More preferably, such a distribution is generated using a model which mimics the actual data but has no intrinsic clustered structures (*i.e.*, a "null hypothesis" model). For example, such distributions may be generated by (a) randomizing the perturbation experiment index i for each cellular constituent X , and (b) calculating the change in compactness which occurs for each distribution, *e.g.*, by increasing the number of clusters from N to $N+1$ (non-hierarchical clustering methods), or by increasing the branching level at which clusters are defined (hierarchical methods).

Such a process is illustrated in Fig. 12 for an exemplary, non-hierarchical embodiment of the clustering methods wherein the perturbation vectors are two-dimensional (*i.e.*, there are two perturbation experiment, $i = 1, 2$) and have lengths $|X| = 2$. Their response vectors are therefore displayed in Fig. 12 as points in two-dimensional space. In the present example, two apparent clusters can be distinguished. These two clusters are shown in Fig. 12A, and comprise a circular cluster and a dumbbell-shaped cluster. The cluster centers are indicated by the triangle symbol (Δ). As is apparent to one skilled in the art, the distribution of perturbation vectors in Fig. 12 could also be divided into three clusters, illustrated in Fig. 12B along with their corresponding centers. As will also be apparent to one skilled in the art, the two new clusters in Fig. 12B are each more compact than the one dumbbell shaped cluster in Fig. 12A. However, such an increase in compactness may not be statistically significant, and so may not be indicative of the actual or unique cellular constituent sets. In particular, the compactness of a set of N clusters may be defined in this example as the inverse of the mean squared distance of each element from its cluster center, *i.e.*, as $1/D_{\text{mean}}^{(N)}$. In general, $D_{\text{mean}}^{(N+1)} < D_{\text{mean}}^{(N)}$. Regardless of whether there are additional "real" cellular constituent sets. Accordingly, the statistical methods of this invention may be used to evaluate the statistical significance of the increased

compactness which occurs, *e.g.*, in the present example, when the number of clusters is increased from $N = 2$ to $N+1 = 3$.

In an exemplary embodiment, the increased compactness is given by the parameter E , which is defined by the formula

$$E = \frac{I_{\text{mean}}^{(N)} - I_{\text{mean}}^{(N+1)}}{I_{\text{mean}}^{(N+1)}} \quad (10)$$

However, other definitions are apparent to those skilled in the art which may also be used in the statistical methods of this invention. In general, the exact definition of E is not crucial provided it is monotonically related to increase in cluster compactness.

The statistical methods of this invention provide methods to analyze the significance of E . Specifically, these methods provide an empirical distribution approach for the analysis of E by comparing the actual increase in compactness, E_0 for actual experimental data, to an empirical distribution of E values determined from randomly permuted data (*e.g.*, by Equation 10 above). In the two-dimensional example illustrated in Fig 12, such a translation comprises, first, randomly swapping the perturbation indices $i = 1, 2$ in each response vector with equal probability. More specifically, the coordinates (*i.e.*, the indices) of the vectors in each cluster being subdivided are "reflected" about the cluster center, *e.g.*, by first translating the coordinate axes to the cluster center as shown in Fig. 12C. The results of such an operation are shown, for the two-dimensional example, in Fig. 12D. Second, the randomly permuted data are re-evaluated by the cluster algorithms of the invention, most preferably by the same cluster algorithm used to determine the original cluster(s), so that new clusters are determined for the permuted data, and a value of E is evaluated for these new clusters (*i.e.*, for splitting one or more of the new clusters). Steps one and two above are repeated for some number of Monte Carlo trials to generate a distribution of E values. Preferably, the number of Monte Carlo trials is from about 50 to about 1000, and more preferably from about 50 to about 100. Finally, the actual increase in compactness, *i.e.*, E_0 , is compared to this empirical distribution of E values. For example, if M Monte Carlo simulation are performed, of which x have E values greater than E_0 , then the confidence level in the number of clusters may be evaluated from $1-x/M$. In particular, if $M = 100$ and $x = 4$, then the confidence level that there is no real significance in increasing the number of clusters is $1 - 4/100 = 96\%$.

The above methods are equally applicable to embodiments comprising hierarchical clusters and/or a plurality of elements (*e.g.*, more than two cellular constituents). For example, the cluster tree illustrated in Fig. 11. This clustering tree was obtained using the *hclust* algorithm for 34 perturbation response profiles comprising 185 cellular constituents

which had significant responses. Using the clusters defined by the branches at LEVEL 2 of this tree, 100 Monte Carlo simulations were performed randomizing the 34 experimental indices and empirical distributions for the improvements in compactness E were generated for each branching in the tree. The actual improvement in compactness E_0 at each branch was compared with its corresponding distribution. These comparisons are shown by the numbers at each branch in Fig. 11. Specifically, these numbers indicate the number of standard deviations in the distribution by which E_0 exceed the average value of E . The indicated significance correspond well with the independently determined biological significance of the branches. For example, the main branch indicated in Fig. 7 by the number five (bottom label) comprises genes regulated via the calcineurin protein, whereas the branch labeled number 7 primarily comprises genes regulated by the Gcn4 transcription factor.

Further, although the Monte Carol methods of the present invention are described above, for exemplary purposes, in terms of the permutation of a perturbation index i , it is readily appreciated by those skilled in the art that such methods may also be used by permuting any index of biological response data which is independent of the cellular constituent index. For example, in some embodiments the response profile data for cellular constituent X may be a function of time, *e.g.*, $X(t)$, with a time index t in addition to or in place of a perturbation index. In such embodiments, the Monte Carlo methods of this invention may also be used by permuting the time index t .

Another aspect of the cluster analysis method of this invention provides the definition of basis vectors for use in profile projection described in the following sections.

A set of basis vectors V has $k \times n$ dimensions, where k is the number of genes and n is the number of genesets.

$$V = \begin{bmatrix} V_1^{(1)} & \dots & V_1^{(n)} \\ \vdots & \ddots & \vdots \\ V_k^{(1)} & \dots & V_k^{(n)} \end{bmatrix} \quad (11)$$

$V_k^{(n)}$ is the amplitude contribution of gene index k in basis vector n . In some embodiments, $V_k^{(n)} = 1$, if gene k is a member of geneset n , and $V_k^{(n)} = 0$ if gene k is not a member of geneset n . In some embodiments, $V_k^{(n)}$ is proportional to the response of gene k in geneset n over the training data set used to define the genesets.

In some preferred embodiments, the elements $V_k^{(n)}$ are normalized so that each basis vector $V^{(n)}$ has unit length by dividing by the square root of the number of genes in geneset

5 n . This produces basis vectors which are not only orthogonal (the genesets derived from cutting the clustering tree are disjoint), but also orthonormal (unit length). With this choice of normalization, random measurement errors in profiles project onto the $V_k^{(n)}$ in such a way that the amplitudes tend to be comparable for each n . Normalization prevents large
10 genesets from dominating the results of similarity calculations.

15 5.2.3. GENESET CLASSIFICATION BASED UPON MECHANISMS OF REGULATION

Genesets can also be defined based upon the mechanism of the regulation of genes.
10 Genes whose regulatory regions have the same transcription factor binding sites are more likely to be co-regulated. In some preferred embodiments, the regulatory regions of the genes of interest are compared using multiple alignment analysis to decipher possible shared
20 transcription factor binding sites (Stormo and Hartzell, 1989, Identifying protein binding sites from unaligned DNA fragments, Proc Natl Acad Sci 86:1183-1187; Hertz and Stormo, 1995, Identification of consensus patterns in unaligned DNA and protein sequences: a large-deviation statistical basis for penalizing gaps, Proc of 3rd Intl Conf on Bioinformatics and Genome Research, Lim and Cantor, eds., World Scientific Publishing Co., Ltd. Singapore, pp. 201-216). For example, as Example 3, *infra*, shows, common promoter sequence
25 responsive to Gcn4 in 20 genes may be responsible for those 20 genes being co-regulated over a wide variety of perturbations.

30 The co-regulation of genes is not limited to those with binding sites for the same transcriptional factor. Co-regulated (co-varying) genes may be in the up-stream/down-stream relationship where the products of up-stream genes regulate the activity of down-stream genes. It is well known to those of skill in the art that there are numerous varieties of
35 gene regulation networks. One of skill in the art also understands that the methods of this invention are not limited to any particular kind of gene regulation mechanism. If it can be derived from the mechanism of regulation that two genes are co-regulated in terms of their activity change in response to perturbation, the two genes may be clustered into a geneset.

40 Because of lack of complete understanding of the regulation of genes of interest, it is often preferred to combine cluster analysis with regulatory mechanism knowledge to derive better defined genesets. For example, in some embodiments statistically significant genesets identified in cluster analysis are compared to biologically significant genesets, *e.g.*,
45 that are identified in regulatory mechanism studies. In some preferred embodiments, K-means clustering may be used to cluster genesets when the regulation of genes of interest is partially known. K-means clustering is particularly useful in cases where the number of
35 genesets is predetermined by the understanding of the regulatory mechanism. In general, K-

mean clustering is constrained to produce exactly the number of clusters desired. Therefore, if promoter sequence comparison indicates the measured genes should fall into three genesets, K-means clustering may be used to generate exactly three genesets with greatest possible distinction between clusters.

5.2.4. REFINEMENT OF GENESETS AND GENESET DEFINITION DATABASE

Genesets found as above may be refined with any of several sources of corroborating information including searches for common regulatory sequence patterns, literature evidence for co-regulation, sequence homology, known shared function, etc.

Databases are particularly useful for the refinement of genesets. In some embodiments, a database containing raw data for cluster analysis of genesets is used for continuously updating geneset definitions. FIG. 3 shows one embodiment of a dynamic geneset database. Data from perturbation experiments (301) are input into data tables (302) in the perturbation database management system (308). Geneset definitions, in the form of basis vectors are continuously generated based upon the updated data in perturbation database using cluster analysis (303) and biological pathway definitions (305, 306). The resulting geneset definition datatable (304) contains updated geneset definitions.

The geneset definitions are used for refining (307) the biological pathway datatables. The geneset definition tables are accessible by user-submitted projection requests. A user (313) can access the database management system by submitting expression profiles (311). The database management system projects (310) the expression profile into a projected expression profile (*see*, section 5.3, *infra*, for a discussion of the projection process). The user-submitted expression profile is optionally added to the perturbation data tables (302).

This dynamic database is constantly productive in the sense that it provides useful geneset definitions with the first, and limited, set of perturbation data. The dynamically updated database continuously refines its geneset definitions to provide more useful geneset definitions as more perturbation data become available.

In some embodiments of the dynamic geneset definition database, the perturbation data and geneset definition data are stored in a series of relational tables in digital computer storage media. Preferably, the database is implemented in distributed system environments with client/server implementation, allowing multiuser and remote access. Access control and usage accounting are implemented in some embodiments of the database system. Relational-database management systems and client/server environments are well documented in the art (Nath, 1995, The Guide to SQL Server, 2nd ed., Addison-Wesley Publishing Co.).

5.3. REPRESENTATION OF GENE EXPRESSION PROFILES BASED UPON BASIS GENESETS

One aspect of the invention provides methods for converting the expression value of genes into the expression value for genesets. This process is referred to as projection. In some embodiments, the projection is as follows:

$$P = [P_1, \dots, P_i, \dots, P_n] = p \bullet V \quad (12)$$

wherein, p is the expression profile, P is the projected profile, P_i is expression value for geneset i and V is a predefined set of basis vectors. The basis vectors have been previously defined in Equation 7 (Section 5.2.2, *supra*) as:

$$V = \begin{bmatrix} V_1^{(1)} & \dots & V_1^{(n)} \\ \vdots & \ddots & \vdots \\ V_k^{(1)} & \dots & V_k^{(n)} \end{bmatrix} \quad (13)$$

wherein $V_k^{(n)}$ is the amplitude of cellular constituent index k of basis vector n .

In one preferred embodiment, the value of geneset expression is simply the average of the expression value of the genes within the geneset. In some other embodiments, the average is weighted so that highly expressed genes do not dominate the geneset value. The collection of the expression values of the genesets is the projected profile.

5.4. APPLICATION OF PROJECTED PROFILES

The projected profiles, i.e., biological state or biological responses expressed in terms of genesets, offer many advantages. This section discusses another aspect of this invention which provides methods of analysis utilizing projected profiles.

5.4.1. ADVANTAGE OF THE PROJECTED PROFILE

One advantage of using projected profiles is that projected profiles are less vulnerable to measurement errors. Assuming independent measurement errors in the data for each cellular constituent, the fractional standard error in the projected profile element is approximately $M_n^{-1/2}$ times the average fractional standard error for the individual cellular constituents, where M_n is the number of cellular constituents in the n 'th geneset. Thus if the average up or down-regulation of the cellular constituents is significant at x standard deviations, then the projected profile element will be significant at $M_n^{1/2} \times x$ standard deviations. This is a standard result for signal-to-noise ratios of mean values; averaging

5 makes a tremendous difference in the probabilities of detection vs. false alarm (*see, e.g.,* Van Trees, 1968, Detection, Estimation, and Modulation Theory Vol I, Wiley & Sons).

Another advantage of the projected profiles is the reduced dimension of the data set. For example, a 48 gene data set is represented by three genesets (example 2) and 194 gene
10 data set is represented by 9 genesets (example 3). This reduction of data dimension greatly facilitates the analysis of profiles.

Yet another advantage of the projected profiles is that projected profiles tend to capture the underlying biology. For example, FIG. 6 shows a clustering tree of 48 genes.

15 Three genesets which correspond to three pathways involving the calcineurin protein, the PDR gene, and the Gcn4 transcription factor, respectively, are identified (Example 1, *infra*).

20 5.4.2. PROFILE COMPARISON AND CLASSIFICATION

Once the basis genesets are chosen, projected profiles P_i may be obtained for any set of profiles indexed by i . Similarities between the P_i may be more clearly seen than between
15 the original profiles p_i for two reasons. First, measurement errors in extraneous genes have been excluded or averaged out. Second, the basis genesets tend to capture the biology of the profiles p_i and so are matched detectors for their individual response components.
25 Classification and clustering of the profiles both are based on an objective similarity metric, call it S , where one useful definition is

$$30 \quad S_{ij} = S(P_i, P_j) = P_i \cdot P_j / (|P_i||P_j|) \quad (14)$$

This definition is the generalized angle cosine between the vectors P_i and P_j . It is the projected version of the conventional correlation coefficient between p_i and p_j . Profile p_i is
35 deemed most similar to that other profile p_j for which S_{ij} is maximum. New profiles may be classified according to their similarity to profiles of known biological significance, such as the response patterns for known drugs or perturbations in specific biological pathways. Sets
40 of new profiles may be clustered using the distance metric

$$30 \quad D_{ij} = 1 - S_{ij} \quad (15)$$

45 where this clustering is analogous to clustering in the original larger space of the entire set of response measurements, but has the advantages just mentioned of reduced measurement error effects and enhanced capture of the relevant biology.

35 The statistical significance of any observed similarity S_{ij} may be assessed using an empirical probability distribution generated under the null hypothesis of no correlation. This
50

5 distribution is generated by performing the projection, Equations (9) and (10) above, for many different random permutations of the constituent index in the original profile p .

10 That is, the ordered set p_i are replaced by $p_{\pi(k)}$ where $\pi(k)$ is a permutation, for ~100 to 1000 different random permutations. The probability of the similarity S_y arising by chance is then the fraction of these permutations for which the similarity S_y (permuted) exceeds the similarity observed using the original unpermuted data.

15 5.4.3. ILLUSTRATIVE DRUG DISCOVERY APPLICATIONS

One aspect of the invention provides methods for drug discovery. In one embodiment, genesets are defined using cluster analysis. The genes within a geneset are indicated as potentially co-regulated under the conditions of interest. Co-regulated genes are further explored as potentially being involved in a regulatory pathway. Identification of genes involved in a regulatory pathway provides useful information for designing and screening new drugs.

20 Some embodiments of the invention employ geneset definition and projection to identify drug action pathways. In one embodiment, the expression changes of a large number of genes in response to the application of a drug are measured. The expression change profile is projected into a geneset expression change profile. In some cases, each of the genesets represents one particular pathway with a defined biological purpose. By examining the change of genesets, the action pathway can be deciphered. In some other cases, the expression change profile is compared with a database of projected profiles obtained by perturbing many different pathways. If the projected profile is similar to a projected profile derived from a known perturbation, the action pathway of the drug is indicated as similar to the known perturbation. Identification of drug action pathways is useful for drug discovery. See, Stoughton and Friend, Methods for Identifying pathways of Drug Action, U.S. Patent Application No. 09/074,983, previously incorporated by reference.

30 In some embodiments of the invention, drug candidates are screened for their therapeutic activity (See, Friend and Hartwell, Drug Screening Method, U.S. Provisional Application No. 60/056,109, filed on August 20, 1998, previously incorporated by reference for all purposes, for a discussion of drug screening methods). In one embodiment, desired drug activity is to affect one particular genetic regulatory pathway. In this embodiment, drug candidates are screened for their ability to affect the geneset corresponding to the regulatory pathway. In another embodiment, a new drug is desired to replace an existing drug. In this embodiment, the projected profiles of drug candidates are compared with that of the existing drug to determine which drug candidate has activities similar to the existing drug.

5 In some embodiments, the method of the invention is used to decipher pathway
arborization and kinetics. When a receptor is triggered (or blocked) by a ligand, the
excitation of the downstream pathways can be different depending on the exact temporal
10 profile and molecular domains of the ligand interaction with the receptor. Simple examples
5 of the differing effects of different ligands are the phenotypical differences that arise
between responses to agonists, partial agonists, negative antagonists, and antagonists, and
that are expected to occur in response to covalent vs. noncovalent binding and activation of
15 different molecular domains on the receptor. See, Ross, Pharmacodynamics: Mechanisms
of Drug Action and the Relationship between Drug Concentration and Effect, in The
10 Pharmacological Basis of Therapeutics (Gilman *et al. ed.*), McGraw Hill, New York, 1996.
FIG. 4A illustrates two different possible responses of a pathway cascade.

20 In some embodiments of the invention, ligands for G protein-coupled receptors
(GPCRs) or other receptors may be investigated using the projection method of the invention
to simplify the observed temporal responses to receptor interactions over the responding
15 genes. In some particularly preferred embodiments, the genesets and temporal profiles
involved are discovered. The profile of temporal responses of a large number of genes are
25 projected onto the predefined genesets to obtain a projected profile of temporal responses.
The projection process simplifies the observed responses so that different temporal
responses may be detected and discriminated more accurately.

30 Figure 4B gives an example of clustering of genes by their temporal response
profiles across several time points. The experiment here was activation of the yeast mating
pathway (same strains, methods, etc. as described earlier) with the yeast α mating
pheromone. Expression responses for all yeast genes ratioed to control (mock treatment)
35 baseline were measured immediately after treatment, and at 15 minutes after treatment, 30,
25 45, 60, 90, and 120 minutes after treatment. This time series of experiments provided the
experiment set for clustering analysis. Each line represents one experiment. A line with an
asterisk represents an experiment that was given low weight in clustering operation. Three
40 of the main cluster groups are illustrated in FIG. 4B, showing systematically distinct
temporal behavior. The first group (early) is responding to the STE12 transcription factor,
30 the second group (adaptive) contains members of the main signaling pathway such as STE2
and STE12 itself that fatigue (show decreasing response) with continued treatment, and the
third group (cell cycle) is associated with the cell cycle perturbations inflicted by the mating
45 response. --

50 It is possible to define augmented basis vectors whose indices cover constituents *and*
35 time points. Projection onto these basis vectors picks out the amplitudes of response in
specific gene groups *and* of specific temporal profiles. Thus, for example, we could

efficiently detect responses such as those shown in the third group in FIG. 4B by projecting a time series of expression profiles onto an augmented basis vector whose elements were nonzero only for the genes included in the third group, and whose nonzero amplitudes varied over the time index according to the average of the temporal response in the third group.

5.4.4. ILLUSTRATIVE DIAGNOSTIC APPLICATIONS

One aspect of the invention provides methods for diagnosing diseases of humans, animals and plants. Those methods are also useful for monitoring the progression of diseases and the effectiveness of treatments.

In one embodiment of the invention, a patient cell sample such as a biopsy from a patient's diseased tissue, is assayed for the expression of a large number of genes. The gene expression profile is projected into a profile of geneset expression values according to a definition of genesets. The projected profile is then compared with a reference database containing reference projected profiles. If the projected profile of the patient matches best with a cancer profile in the database, the patient's diseased tissue is diagnosed as being cancerous. Similarly, when the best match is to a profile of another disease or disorder, a diagnosis of such other disease or disorder is made.

In another embodiment, a tissue sample is obtained from a patient's tumor. The tissue sample is assayed for the expression of a large number of genes of interest. The gene expression profile is projected into a profile of geneset expression values according to a definition of genesets. The projected profile is compared with projected profiles previously obtained from the same tumor to identify the change of expression in genesets. A reference library is used to determine whether the geneset changes indicate tumor progression. A similar method is used to stage other diseases and disorders. Changes of geneset expression values in a profile obtained from a patient under treatment can be used to monitor the effectiveness of the treatment, for example, by comparing the projected profile prior to treatment with that after treatment.

5.4.5. RESPONSE PROFILE CLASSIFICATION BY CLUSTER ANALYSIS

The methods of the present invention are not simply limited to grouping cellular constituents, such as genes, according to their degrees of co-variation (*e.g.*, by co-regulation). In particular, the cluster analysis and other statistical classification methods described above to analyze the co-variation of cellular constituents may also be used to analyze biological response profiles and to group or cluster such profiles according to the similarity of their biological responses. Thus, for example, whereas Section 5.2.2 above describes methods for analyzing cellular constituent "vectors" $X = \{X_i\}$ where i is the

5 response profile index, the methods and equations described in Section 5.2.2 may also be used to analyze response profile vectors $v^{(m)} = \{v_i^{(m)}\}$ where m is the response profile index, and i is the cellular constituent index.

10 Such analyses may be performed, *e.g.*, using the exact same clustering algorithms, including 'hclust,' as described in Section 5.2.2 above, and using the exact same distance metrics. For example, Section 5.2.2 above describes using the distance metric $I = 1 - r$, where r is the normalized dot product $X \cdot Y / |X| |Y|$, for the comparison of cellular constituent vectors X and Y . As is readily apparent to those skilled in the art, the same distance metric
15 may also be used to evaluate response profile vectors $v^{(m)}$ and $v^{(n)}$, by evaluating
20 $r = v^{(m)} \cdot v^{(n)} / |v^{(m)}| |v^{(n)}|$. Similar application of the other aspects of the clustering methods described above in Section 5.2.2, including the other distance metrics and the significance tests, are also apparent to those skilled in the art and may be used in the present invention.

25 The analytical methods of this invention thus include methods of "two-dimensional" cluster analysis. Such two-dimensional cluster analysis methods simply comprise (1) clustering cellular constituents into sets that are co-varying in biological profiles, and (2) clustering biological profiles into sets that effect similar cellular constituents (preferably in similar ways). The two clustering steps may be performed in any order and according to the methods described above.

30 Such two-dimensional clustering techniques are useful, as noted above, for identifying sets of genes and perturbations of particular interest. For example, the two-dimensional clustering techniques of this invention may be used to identify sets of cellular constituents (*i.e.*, changes in levels of expression or abundance) and/or experiments that are associated with a particular biological effect of interest, such as a drug effect or a particular disease or disease state. The two-dimensional clustering techniques of this invention may
35 also be used, *e.g.*, to identify sets of cellular constituents and/or experiments that are associated with a particular biological pathway of interest.

40 Still further, the above described two-dimensional clustering techniques can be used to identify perturbations that cause changes in the levels of expression or abundance of particular cellular constituents of interest or in particular co-varying sets of cellular constituents (*e.g.*, particular genesets) of interest. For example, in one preferred embodiment of the invention, such sets of cellular constituents and/or perturbations are used to determine consensus profiles for a particular biological response of interest. In other
45 embodiments, identification of such sets of cellular constituents and/or experiments provide more precise indications of groupings cellular constituents, such as identification of genes
50 involved in a particular biological pathway or response of interest.

5 Accordingly, another preferred embodiment of the present invention provides
methods for identifying cellular constituents, particularly genes (*e.g.*, new genes) or
genesets, whose change (*e.g.*, in levels of expression or abundance) is associated with and/or
involved in a particular biological effect of interest *e.g.*, a particular biological pathway, the
10 effect of one or more drugs, a particular disease or disease state or, alternatively, a particular
treatment or therapy (*e.g.*, a particular drug treatment or drug therapy). Such cellular
constituents are identified according to the cluster-analysis methods described above. Such
cellular constituents (*e.g.*, genes) may be previously unknown cellular constituents, or
15 known cellular constituents that were not previously known to be associated with the
biological effect of interest.

Considering, for example, the particular embodiment of identifying cellular
constituents associated with a disease or disease state, using the two-dimensional clustering
20 methods described hereinabove biological profiles that cluster with perturbations associated
with a particular disease or disease state can be identified and examined to identify cellular
constituents and/or cellular constituent sets (*e.g.*, genesets) that consistently change (*e.g.*, in
levels of expression or abundance) within such profiles. Such cellular constituents are useful
25 as markers (*e.g.*, genetic markers in the case of genes and genesets) for the particular disease
or disease state. In particular, changes in such markers (*e.g.*, in their level of expression or
abundance) observed in a biological sample obtained, *e.g.*, from a patient, can therefore be
used to diagnose the particular disease or disease state in that patient. Those cellular
30 constituents that are particularly useful as markers (*e.g.*, of a disease or disease state), and
are therefore preferred in the present invention, are those cellular constituents that change
(*e.g.*, in their level of expression or abundance) in perturbations associated with a particular
biological effect (*e.g.*, a particular disease or disease state) of interest but do not change in
35 other perturbations; *i.e.*, in perturbations that are not associated with the particular
biological effect of interest.

The present invention further provides methods for the iterative refinement of
cellular constituent sets and/or clusters of response profiles (such as consensus profiles). In
40 particular, dominant features in each set of cellular constituents and or profiles identified by
the cluster analysis methods of this invention may be blanked out, *e.g.*, by setting their
elements to zero or to the mean data value of the set. The blanking out of dominant features
may done by a user, *e.g.*, by manually selecting features to blank out, or automatically, *e.g.*,
45 by automatically blanking out those elements whose response amplitudes are above a
selected threshold. The cluster analysis methods of the invention are then reapplied to the
cellular constituent and/or profile data. Such iterative refinement methods may be used, *e.g.*,

5 to identify other potentially interesting but more subtle cellular constituent and/or experiment associations that were not identified because of the dominant features.

10 More generally, and as is also apparent to those skilled in the art, the clustering methods of this invention may be used to cluster each dimension of any N-dimensional array of biological (or other) data, wherein N may be any positive integer. For example, in some 5 embodiments, the biological data may comprise matrices (*i.e.*, tables) of values $v^{(m)}_i(t)$ which describe the change of cellular constituent *i* in response to perturbation *m* after a time *t*. The clustering methods of the present invention may be used, in such embodiments, to cluster 15 (1) the cellular constituent index *i*, (2) the perturbation response index *m*, and (3) the time index 10 *t*. Other embodiments are also apparent to those skilled in the art.

20 5.4.6. REMOVAL OF PROFILE ARTIFACTS

The projection methods of the present invention, including the methods described in Section 5.2 above, may also be used to remove unwanted response components (*i.e.*, 15 "artifacts") from biological profile data. Frequently, when such profile data are obtained there are one or more poorly controlled variables which lead to measured patterns of cellular constituents (*e.g.*, measured gene expression patterns) which are, in fact, artifacts of the 25 measurement process and are not part of the actual biological state or response (such as a perturbation response) being measured. Exemplary variables which may produce artifacts in 30 biological profile data include, but are by no means limited to, cell culture density and temperature and hybridization temperature, as well as concentrations of total RNA and/or hybridization reagents.

For example, Di Risi *et al.* (1997, *Science* 278:680-686) describe measurements 35 using microarrays of *S. cerevisiae* cDNA levels during the change from anaerobic to aerobic growth (*i.e.*, the "diauxic shift"). However, if one of two nominally identical cell cultures 25 has unintentionally progressed further into the diauxic shift than the other, their expression ratios will reflect that transcriptional changes associated with this shift. Such artifacts 40 potentially confuse the measurements of the true transcriptional responses being sought. These artifacts may be "projected out" by removing or suppressing their patterns in the data.

30 In preferred embodiments, the artifact patterns in the data are known. In general, artifact patterns may be determined from any source of knowledge of the genes and relative amplitudes of response associated with such artifacts. For example, the artifact patterns may 45 be derived from experiments with intentional perturbations of the suspected causative variables. In another embodiment, the artifact patterns may be determined from clustering 35 analysis of control experiments where the artifacts arise spontaneously.

In such preferred embodiments, the contribution of known artifacts may be solved for and subtracted from the measured biological profile $p = \{p_i\}$, e.g., by determining the best scaling coefficients α_n for the contribution of artifact n to the profile. Preferably, the coefficients α_n are found by determining the values of α_n which minimize an objective function of the difference between the measured profile and the scaled contribution of the artifacts. For example, the coefficients α_n may be determined by the least square minimization

$$\min_{\alpha_n} \left\{ \sum_i \left(p_i - \sum_n \alpha_n A_{n,i} \right)^2 w_i \right\} \quad (16)$$

wherein $A_{n,i}$ is the amplitude of artifact n on the measurement of cellular constituent i . w_i is an optional weighting factor selected by a user according to the relative certainty or significance of the measured value of cellular constituent i (i.e., of p_i).

The "cleaned" profile $p^{(clean)}$ in which the artifacts are effectively removed, is then given by the equation

$$p_i^{(clean)} = p_i - \sum_n \alpha_n A_{n,i} \quad (17)$$

wherein the coefficients α_n are determined, e.g., from equation 16 above.

In other embodiments, the profile p may be compared to a library of artifact signatures $A_s = \{A_{s,i}\}$ of different severity. In such embodiments, the "cleaned" profile is determined by pattern matching against this library to determine the particular template which has greatest similarity to the profile p . In such embodiments, the cleaned profile is given by $p_k^{(clean)} = p_k - A_{s,i}$, wherein the signature A_s is determined, e.g., by solving the equation

$$\min_s \left\{ \sum_i \left(p_i - A_{s,i} \right)^2 w_i \right\} \quad (18)$$

5.4.7. PROJECTED TITRATION CURVES

In many instances, it may be desirable to measure the response of a biological system to a plurality of graded levels of exposure to a particular perturbation. For example, during the process of drug discovery, it is often necessary or desirable to measure the response of a biological system to graded levels of exposure to a particular drug or drug candidate, e.g., to

determine the therapeutic and/or toxic effects of the drug or drug candidate. In other instances, it may be desirable to measure the effect on a biological system, *e.g.*, of graded expression of a particular gene or gene product, such as by the methods described in Section 5.8.1 below. For example, Fig. 13 shows the transcriptional responses of the largest responding genes of *S. cerevisiae* to different concentrations of the drug FK506, as described by Marton *et al.*, 1998, *Nature Medecine* 4:1293-1301).

The methods of the present invention may also be used to project such "titration responses" onto co-varying cellular constituent sets, such as onto genesets. Such "titration responses" typically comprise a plurality of biological responses at graded levels of exposure to a particular perturbation (*e.g.*, graded levels of exposure to the drug FK506, as illustrated in Fig. 13). Thus, projected titration responses may be generated by projecting the biological response profile obtained at each level of the perturbation (*e.g.*, at each concentration of the drug) according to any of the methods described above in Sections 5.2 and 5.3. For example, Fig. 15 shows the projected titration response curves of Fig. 13. In this particular example, the projection comprises averaging the response of each geneset with normalization such that the length of each basis geneset is unity, as described, *e.g.*, in Section 5.3 above.

In preferred embodiments, the projected titration responses are interpolated, *e.g.*, by fitting to some model function of the perturbation. For example, in Fig. 14 the projected titration response curves have been fit to Hill Functions of the form shown in Equation 3 above. However, other model function known in the art may be used. Alternatively, the projected titration response curves may be interpolated by means of spline-fitting, wherein each projected titration curve is interpolated by summing products of an appropriate spline interpolation function S multiplied by the measured data values, as provided by the equation

$$P(u) = \sum_i S(u - u_i) P(u_i) \quad (19)$$

The variable " u " refers to an arbitrary value of the perturbation (*e.g.*, the drug exposure level or concentration) where the projected titration response P is to be evaluated. The variable " u_i " refers to discrete values of the perturbation at which response profiles were actually measured. In general, S may be any smooth, or at least piece-wise continuous, function of limited support having a width characteristic of the structure expected in the projected titration response functions. An exemplary width can be chosen to be the distance over which the projected titration response function being interpolated rises from 10% to 90% of its asymptotic value. Exemplary S functions include linear and Gaussian interpolation.

Compared to the confusing tangle of curves in Fig. 13, it is clear from the projected geneset titration responses shown in Fig. 14 that certain genesets respond at different critical

5 concentrations of FK506 (given by u_0 in Equation 3), and with different power law exponent
(n in Equation 3) than do other genesets. Fig. 15 shows the contours of chi-squared plotted
around the values of the two Hill coefficients (u_0 and n in Equation 3) derived for each
10 geneset. The plot shows that the apparent visual distinctions in Fig. 14 are statistically
5 significant. Specifically, the Hill coefficients are distinguished in both their sharpness (*i.e.*,
the power law exponent n , vertical axis) and in their critical concentrations (*i.e.*, u_0 ,
horizontal axis). Thus, individual genesets may be distinguished, *e.g.*, according to the form
of their titration responses.

15 As expected, the different genesets in a titration response profile are also biologically
10 significant. For example, supporting experiments using FK506 in gene deletion strains of *S.*
cerevisiae and the analysis of gene regulatory sequence regions show that the geneset
identified in Fig. 14 for the titration response of *S. cerevisiae* to FK506 have biological
20 identities (see Marton *et al.*, *supra*). These identities are indicated by the annotations in Fig.
14. Thus, the titration behaviors of different genesets are also indicative of different
15 biological pathways. For example, the curves labeled "GCN4-dependent" in Fig. 14 are
responses of the sets of genes whose responses are mediated via the transcription factor
protein Gcn4 (see, Marton *et al.*, *supra*), while the gentler responses in Fig. 14, labeled
25 "GCN4-independent" are for the sets of genes which respond to FK506 whether or not the
calcineurin or Gcn4 proteins are present.

30 In other instances, it may be desirable to measure the state of a biological sample
over a time interval. In particular, it is often desirable to monitor the changing biological
state of a sample that occurs over time, *e.g.*, in association with a particular biological
process or effect. Such biological processes may include, but are by no means limited to,
35 meiosis, mitosis, and cell differentiation. Changes in the biological state of a sample that
25 occur over a time interval may also include changes in response to a particular perturbation
such as exposure to one or more drugs, or a change in the environment. Monitoring changes
of the biological state of a sample over time may simply comprise a plurality of
40 measurements of the time interval during which the biological process or effect of interest
occurs. The methods of the present invention may be used to project such "temporal
30 measurements" of the biological state onto co-varying cellular constituent sets such as onto
genesets. In particular, as is apparent to those skilled in the art, such temporal measurements
45 may be analyzed according to the methods described above for measuring titration
responses.

5.4.8. USE OF GENESETS IN MICROARRAYS

The genesets of the present invention are also useful in the design and preparation of microarrays. In particular, using the methods of the invention a skilled artisan can readily select and prepare probes for a microarray wherein the microarray contains specific individual probes for less than all the genes in the genome and less than all the genes in a geneset. In such embodiments, the microarray contains one or two or more individual probes, each of which hybridizes to an expression product (*e.g.*, mRNA, or cDNA or cRNA derived therefrom) within a single geneset for a desired number of genesets. Thus, for example, changes in the expression of all or most of the genes in the entire genome of a cell or organism can thereby be monitored by use of a surrogate and on a single microarray by measuring expression of the group of genesets that are representative of all or most of the genes of the genome. Such microarrays can be prepared, *e.g.*, as described in Section 5.7, below, using the selected probes and are therefore part of the present invention.

For example, in preferred embodiments, genesets are identified, as described in the above sections, for a biological sample (*e.g.*, a cell or organism) of interest. In general, the number of genesets identified and for which probes appear in a microarray can be anywhere from 50 to 1,000. Preferably, however, the number of genesets for which probes appear in a microarray will be fewer than 500, more preferably from 100 to 500, and still more preferably from 100 to 200. Representative genes are then selected from each geneset identified, and probes are prepared that hybridize to the nucleotide sequence of each representative gene. Preferably, no more than ten representative genes are selected from each geneset. More preferably, however, the number of representative genes selected from each geneset for which probes appear on the microarray is no more than five, no more than four, no more than three or no more than two. In fact, most preferably only a single representative gene is selected from each geneset for which one or more probes appear on the microarray. For at least one geneset, and preferably for most or all of the genesets, the number of representative genes for which probes appear on the microarray is less than the total number of genes in the geneset. In certain preferred embodiments, at least one representative gene for which probes appear on the microarray is selected from all of the genesets identified for the cell or organism. In other embodiments, the representative genes for which probes appear on the microarray are selected solely from genesets that are associated with one or more particular biological states of interest. For example, in certain embodiments, the representative genes are selected from genesets associated with a particular disease or disease state. In other embodiments, the representative genes are selected from genesets whose change in expression is associated with a particular drug or with a particular therapy including, for example, genesets whose change in expression is

5 associated with drug or therapeutic efficacy or genesets whose change in expression is
associated with drug resistance or therapeutic failure. Thus, for example, in certain
embodiments the total number of genesets for which probes are present on a microarray is
10 less than 1,000, less than 500, less than 200, less than 100, less than 50, less than 30, less
5 than 20, or less than 10.

5.5. COMPUTER IMPLEMENTATION

15 The analytic methods described in the previous subsections can preferably be
implemented by use of the following computer systems and according to the following
10 programs and methods. FIG. 5 illustrates an exemplary computer system suitable for
implementation of the analytic methods of this invention. Computer system 501 is
20 illustrated as comprising internal components and being linked to external components. The
internal components of this computer system include processor element 502 interconnected
with main memory 503. For example, computer system 501 can be an Intel Pentium®-
15 based processor of 200 MHz or greater clock rate and with 32 MB or more of main memory.

25 The external components include mass storage 504. This mass storage can be one or
more hard disks (which are typically packaged together with the processor and memory).
Such hard disks are typically of 1 GB or greater storage capacity. Other external
components include user interface device 505, which can be a monitor, together with
30 inputting device 506, which can be a "mouse", or other graphic input devices (not illustrated),
and/or a keyboard. A printing device 508 can also be attached to the computer 501.

Typically, computer system 501 is also linked to network link 507, which can be part
of an Ethernet link to other local computer systems, remote computer systems, or wide area
communication networks, such as the Internet. This network link allows computer system
35 501 to share data and processing tasks with other computer systems.

Loaded into memory during operation of this system are several software
components, which are both standard in the art and special to the instant invention. These
software components collectively cause the computer system to function according to the
40 methods of this invention. These software components are typically stored on mass storage
30 504. Software component 510 represents the operating system, which is responsible for
managing computer system 501 and its network interconnections. This operating system can
be, for example, of the Microsoft Windows' family, such as Windows 95, Windows 98, or
45 Windows-NT. Software component 511 represents common languages and functions
conveniently present on this system to assist programs implementing the methods specific to
35 this invention. Many high or low level computer languages can be used to program the
analytic methods of this invention. Instructions can be interpreted during run-time or
50

5 compiled. Preferred languages include C/ C++, FORTRON and JAVA®. Most preferably,
the methods of this invention are programmed in mathematical software packages which
allow symbolic entry of equations and high-level specification of processing, including
10 algorithms to be used, thereby freeing a user of the need to procedurally program individual
5 equations or algorithms. Such packages include Matlab from Mathworks (Natick, MA),
Mathematica from Wolfram Research (Champaign, IL), or S-Plus from Math Soft
(Cambridge, MA). Accordingly, software component 512 represents the analytic methods of
this invention as programmed in a procedural language or symbolic package. In a preferred
15 embodiment, the computer system also contains a database 513 of perturbation response
10 curves.

In an exemplary implementation, to practice the methods of the present invention, a
user first loads expression profile data into the computer system 501. These data can be
20 directly entered by the user from monitor 505 and keyboard 506, or from other computer
systems linked by network connection 507, or on removable storage media such as a CD-
15 ROM or floppy disk (not illustrated) or through the network (507). Next the user causes
execution of expression profile analysis software 512 which performs the steps of clustering
25 co-varying genes into genesets.

In another exemplary implementation, a user first loads expression profile data into
the computer system. Geneset profile definitions are loaded into the memory from the
20 storage media (504) or from a remote computer, preferably from a dynamic geneset database
system, through the network (507). Next the user causes execution of projection software
30 which performs the steps of converting expression profile to projected expression profiles.

In yet another exemplary implementation, a user first loads a projected profile into
the memory. The user then causes the loading of a reference profile into the memory. Next,
35 the user causes the execution of comparison software which performs the steps of
25 objectively comparing the profiles.

This invention also provides software for geneset definition, projection, and analysis
for projected profiles. One embodiment of the software contains a module capable of
40 executing the cluster analysis of the invention. The module is capable of causing a processor
30 of a computer system to execute steps of (a) receiving a perturbation experiment data table,
(b) receiving the criteria for geneset selection, (c) cluster the perturbation data into a
45 clustering tree, and (d) defining genesets based upon the clustering tree and the criteria for
geneset selection.

Another embodiment of the software contains a module capable of executing the
35 projection operation by causing a processor of a computer system to execute steps of (a)

5 receiving a geneset definition, (b) receiving an expression profile, and (c) calculating a projected profile based upon the geneset definition and the expression profile.

Yet another embodiment of the software contains a module capable of executing the comparison operation by causing a processor of a computer system to execute steps of
10 5 (a) receiving a projected profile of a biological sample, (b) receiving a reference profile, and (c) calculating an objective measurement of the similarity between the two profiles.

Alternative computer systems and software for implementing the analytic methods of this invention will be apparent to one of skill in the art and are intended to be comprehended within the accompanying claims. In particular, the accompanying claims are intended to
15 10 include the alternative program structures for implementing the methods of this invention that will be readily apparent to one of skill in the art.

20 5.6. ANALYTIC KIT IMPLEMENTATION

In a preferred embodiment, the methods of this invention can be implemented by use
15 of kits for determining the responses or state of a biological sample. Such kits contain microarrays, such as those described in Subsections below. The microarrays contained in such kits comprise a solid phase, *e.g.*, a surface, to which probes are hybridized or bound at a
25 known location of the solid phase. Preferably, these probes consist of nucleic acids of known, different sequence, with each nucleic acid being capable of hybridizing to an RNA
30 species or to a cDNA species derived therefrom. In particular, the probes contained in the kits of this invention are nucleic acids capable of hybridizing specifically to nucleic acid sequences derived from RNA species which are known to increase or decrease in response to perturbations to the particular protein whose activity is determined by the kit. The probes
35 25 hybridize to RNA species that are not increased in response to perturbations to the particular protein whose activity is determined by the kit.

In a preferred embodiment, a kit of the invention also contains a database of geneset definitions such as the databases described above or an access authorization to use the
40 database described above from a remote networked computer.

30 In another preferred embodiment, a kit of the invention further contains expression profile projection and analysis software capable of being loaded into the memory of a computer system such as the one described *supra* in the subsection, and illustrated in FIG. 5. The expression profile analysis software contained in the kit of this invention, is essentially
45 identical to the expression profile analysis software 512 described above.

35 Alternative kits for implementing the analytic methods of this invention will be apparent to one of skill in the art and are intended to be comprehended within the
50

5 accompanying claims. In particular, the accompanying claims are intended to include the alternative program structures for implementing the methods of this invention that will be readily apparent to one of skill in the art.

10 5 5.7. METHODS FOR DETERMINING BIOLOGICAL RESPONSE

This invention utilizes the ability to measure the responses of a biological system to a large variety of perturbations. This section provides some exemplary methods for measuring biological responses. One of skill in the art would appreciate that this invention is not
15 limited to the following specific methods for measuring the responses of a biological system.

10 5.7.1. TRANSCRIPT ASSAY USING DNA ARRAY

This invention is particularly useful for the analysis of gene expression profiles. One aspect of the invention provides methods for defining co-regulated genesets based upon the correlation of gene expression. Some embodiments of this invention are based on measuring
20 the transcriptional rate of genes.

The transcriptional rate can be measured by techniques of hybridization to arrays of nucleic acid or nucleic acid mimic probes, described in the next subsection, or by other gene expression technologies, such as those described in the subsequent subsection. However measured, the result is either the absolute, relative amounts of transcripts or response data
25 including values representing RNA abundance ratios, which usually reflect DNA expression ratios (in the absence of differences in RNA degradation rates).

In various alternative embodiments of the present invention, aspects of the biological state other than the transcriptional state, such as the translational state, the activity state, or mixed aspects can be measured.

35 Preferably, measurement of the transcriptional state is made by hybridization to transcript arrays, which are described in this subsection. Certain other methods of transcriptional state measurement are described later in this subsection.

In a preferred embodiment the present invention makes use of "transcript arrays" (also called herein "microarrays"). Transcript arrays can be employed for analyzing the
40 transcriptional state in a biological sample and especially for measuring the transcriptional states of a biological sample exposed to graded levels of a drug of interest or to graded perturbations to a biological pathway of interest.

In one embodiment, transcript arrays are produced by hybridizing detectably labeled polynucleotides representing the mRNA transcripts present in a cell (e.g., fluorescently
45 labeled cDNA synthesized from total cell mRNA) to a microarray. A microarray is a surface with an ordered array of binding (e.g., hybridization) sites for products of many of the genes
50

5 in the genome of a cell or organism, preferably most or almost all of the genes. Microarrays can be made in a number of ways, of which several are described hereinbelow. However produced, microarrays share certain characteristics: The arrays are reproducible, allowing multiple copies of a given array to be produced and easily compared with each other.

10 5 Preferably, the microarrays are made from materials that are stable under binding (*e.g.*, nucleic acid hybridization) conditions. The microarrays are preferably small, *e.g.*, between about 5 cm² and 25 cm², preferably about 12 to 13 cm². However, both larger and smaller arrays are also contemplated and may be preferable, *e.g.*, for simultaneously evaluating a very large number of different probes.

15 10 Preferably, a given binding site or unique set of binding sites in the microarray will specifically bind (*e.g.*, hybridize) to the product of a single gene or gene transcript from a cell or organism (*e.g.*, to a specific mRNA or to a specific cDNA derived therefrom). However, as discussed above, in general other, related or similar sequences will cross hybridize to a given binding site.

20 15 The microarrays used in the methods and compositions of the present invention include one or more test probes, each of which has a polynucleotide sequence that is complementary to a subsequence of RNA or DNA to be detected. Each probe preferably has a different nucleic acid sequence, and the position of each probe on the solid surface of the array is preferably known. Indeed, the microarrays are preferably addressable arrays, more 25 preferably positionally addressable arrays. More specifically, each probe of the array is preferably located at a known, predetermined position on the solid support such that the identity (*i.e.*, the sequence) of each probe can be determined from its position on the array (*i.e.*, on the support or surface).

30 35 Preferably, the density of probes on a microarray is about 100 different (*i.e.*, non-identical) probes per 1 cm² or higher. More preferably, a microarray used in the methods of the invention will have at least 550 probes per 1 cm², at least 1,000 probes per 1 cm², at least 1,500 probes per 1 cm² or at least 2,000 probes per 1 cm². In a particularly preferred embodiment, the microarray is a high density array, preferably having a density of at least about 2,500 different probes per 1 cm². The microarrays used in the invention therefore 40 preferably contain at least 2,500, at least 5,000, at least 10,000, at least 15,000, at least 20,000, at least 25,000, at least 50,000 or at least 55,000 different (*i.e.*, non-identical) probes.

45 50 In one embodiment, the microarray is an array (*i.e.*, a matrix) in which each positions represents a discrete binding site for a product encoded by a gene (*i.e.*, for an mRNA or for a cDNA derived therefrom). For example, in various embodiments, the microarrays of the invention can comprise binding sites for products encoded by fewer than 50% of the genes

5 in the genome of an organism. Alternatively, the microarrays of the invention can have binding sites for the products encoded by at least 50%, at least 75%, at least 85%, at least 90%, at least 95%, at least 99% or 100% of the genes in the genome of an organism or, alternatively, for representative genes of genesets encompassing the foregoing percentages
10 of genes in the genome. In other embodiments, the microarrays of the invention can have binding sites for products encoded by fewer than 50%, by at least 50%, by at least 75%, by at least 85%, by at least 90%, by at least 95%, by at least 99% or by 100% of the genes expressed by a cell of an organism or, alternatively, for representative genes of genesets encompassing the foregoing percentages of genes in the genome. The binding site can be a
15 DNA or DNA analog to which a particular RNA can specifically hybridize. The DNA or DNA analog can be, e.g., a synthetic oligomer, a full length cDNA, a less-than full length cDNA, or a gene fragment.

20 Preferably, the microarrays used in the invention have binding sites (i.e., probes) for one or more genes relevant to the action of a drug of interest or in a biological pathway of interest. A "gene" is identified as an open reading frame (ORF) that encodes a sequence of
25 preferably at least 50, 75, or 99 amino acid residues from which a messenger RNA is transcribed in the organism or in some cell or cells of a multicellular organism. The number of genes in a genome can be estimated from the number of mRNAs expressed by the cell or organism, or by extrapolation of a well characterized portion of the genome. When the
30 genome of the organism of interest has been sequenced, the number of ORFs can be determined and mRNA coding regions identified by analysis of the DNA sequence. For example, the genome of *Saccharomyces cerevisiae* has been completely sequenced and is reported to have approximately 6275 ORFs encoding sequences longer than 99 amino acid residues in length. Analysis of these ORFs indicates that there are 5,885 ORFs that are
35 likely to encode protein products (Goffeau *et al.*, 1996, *Science* 274:546-567). In contrast, the human genome is estimated to contain approximately 10^5 genes.

40 It will be appreciated that when cDNA complementary to the RNA of a cell is made and hybridized to a microarray under suitable hybridization conditions, the level of hybridization to the site in the array corresponding to any particular gene will reflect the
30 prevalence in the cell of mRNA transcribed from that gene. For example, when detectably labeled (e.g., with a fluorophore) cDNA complementary to the total cellular mRNA is hybridized to a microarray, the site on the array corresponding to a gene (i.e., capable of
45 specifically binding the product of the gene) that is not transcribed in the cell will have little or no signal (e.g., fluorescent signal), and a gene for which the encoded mRNA is prevalent
35 will have a relatively strong signal.

5 In preferred embodiments, cDNAs from two different cells are hybridized to the binding sites of the microarray. In the case of drug responses one biological sample is exposed to a drug and another biological sample of the same type is not exposed to the drug. In the case of pathway responses one cell is exposed to a pathway perturbation and another
10 cell of the same type is not exposed to the pathway perturbation. The cDNA derived from each of the two cell types are differently labeled so that they can be distinguished. In one embodiment, for example, cDNA from a cell treated with a drug (or exposed to a pathway perturbation) is synthesized using a fluorescein-labeled dNTP, and cDNA from a second cell, not drug-exposed, is synthesized using a rhodamine-labeled dNTP. When the two
15 cDNAs are mixed and hybridized to the microarray, the relative intensity of signal from each cDNA set is determined for each site on the array, and any relative difference in abundance of a particular mRNA detected.

20 In the example described above, the cDNA from the drug-treated (or pathway perturbed) cell will fluoresce green when the fluorophore is stimulated and the cDNA from the untreated cell will fluoresce red. As a result, when the drug treatment has no effect, either directly or indirectly, on the relative abundance of a particular mRNA in a cell, the mRNA will be equally prevalent in both cells and, upon reverse transcription, red-labeled and green-labeled cDNA will be equally prevalent. When hybridized to the microarray, the binding site(s) for that species of RNA will emit wavelengths characteristic of both
25 fluorophores (and appear brown in combination). In contrast, when the drug-exposed cell is treated with a drug that, directly or indirectly, increases the prevalence of the mRNA in the cell, the ratio of green to red fluorescence will increase. When the drug decreases the mRNA prevalence, the ratio will decrease.

30 The use of a two-color fluorescence labeling and detection scheme to define alterations in gene expression has been described, *e.g.*, in Shena *et al.*, 1995, Quantitative monitoring of gene expression patterns with a complementary DNA microarray, *Science* 270:467-470, which is incorporated by reference in its entirety for all purposes. An advantage of using cDNA labeled with two different fluorophores is that a direct and internally controlled comparison of the mRNA levels corresponding to each arrayed gene in
35 two cell states can be made, and variations due to minor differences in experimental conditions (*e.g.*, hybridization conditions) will not affect subsequent analyses. However, it will be recognized that it is also possible to use cDNA from a single cell, and compare, for example, the absolute amount of a particular mRNA in, *e.g.*, a drug-treated or pathway-perturbed cell and an untreated cell.

5.7.1.1. PREPARING NUCLEIC ACIDS FOR MICROARRAYS

As noted above, the "binding site" to which a particular cognate cDNA specifically hybridizes is usually a nucleic acid or nucleic acid analogue attached at that binding site. In one embodiment, the binding sites of the microarray are DNA polynucleotides corresponding to at least a portion of each gene in an organism's genome. These DNAs can be obtained by, *e.g.*, polymerase chain reaction (PCR) amplification of gene segments from genomic DNA, cDNA (*e.g.*, by RT-PCR), or cloned sequences. PCR primers are chosen, based on the known sequence of the genes or cDNA, that result in amplification of unique fragments (*i.e.*, fragments that do not share more than 10 bases of contiguous identical sequence with any other fragment on the microarray). Computer programs are useful in the design of primers with the required specificity and optimal amplification properties. *See, e.g.*, Oligo version 5.0 (National Biosciences). In the case of binding sites corresponding to very long genes, it will sometimes be desirable to amplify segments near the 3' end of the gene so that when oligo-dT primed cDNA probes are hybridized to the microarray, less-than-full length probes will bind efficiently. Typically each gene fragment on the microarray will be between 50 bp and 50,000 bp, between 50 bp and 2000 bp, more typically between 100 bp and 1000 bp, and usually between 300 bp and 800 bp in length. PCR methods are well known and are described, for example, in Innis *et al.* eds., 1990, PCR Protocols: A Guide to Methods and Applications, Academic Press Inc., San Diego, CA, which is incorporated by reference in its entirety for all purposes. It will be apparent that computer controlled robotic systems are useful for isolating and amplifying nucleic acids.

An alternative, preferred means for generating the polynucleotide probes for a microarray used in the methods and compositions of the invention is by synthesis of synthetic polynucleotides or oligonucleotides, *e.g.*, using N-phosphonate or phosphoramidite chemistries (Froehler *et al.*, 1986, *Nucleic Acid Res.* 14:5399-5407; McBride *et al.*, 1983, *Tetrahedron Lett.* 24:246-248). Synthetic sequences are typically between 4 and 500 bases in length, between 15 and 500 bases in length, more typically between 4 and 200 bases in length, even more preferably between 15 and 150 bases in length and still more preferably between 20 and 50 bases in length. In embodiments wherein shorter oligonucleotide probes are used, synthetic nucleic acid sequences less than 40 bases in length are preferred, more preferably between 15 and 30 bases in length. In embodiments wherein longer oligonucleotide probes are used, synthetic nucleic acid sequences are preferably between 40 and 80 bases in length, more preferably between 40 and 70 bases in length and even more preferably between 50 and 60 bases in length. In some embodiments, synthetic nucleic acids include non-natural bases, such as, but not limited to, inosine. As noted above, nucleic acid analogs may be used as binding sites for hybridization. An example of a suitable nucleic

acid analog is peptide nucleic acid (see, *e.g.*, Egholm *et al.*, 1993, *Nature* 363:566-568; U.S. Patent No. 5,539,083).

In an alternative embodiment, the binding (hybridization) sites are made from plasmid or phage clones of genes, cDNAs (*e.g.*, expressed sequence tags), or inserts therefrom (Nguyen *et al.*, 1995, Differential gene expression in the murine thymus assayed by quantitative hybridization of arrayed cDNA clones, *Genomics* 29:207-209). In yet another embodiment, the polynucleotide of the binding sites is RNA.

5.7.1.2. ATTACHING NUCLEIC ACIDS TO THE SOLID SURFACE

The nucleic acid or analogue are attached to a solid support, which may be made from glass, plastic (*e.g.*, polypropylene, nylon), polyacrylamide, nitrocellulose, or other materials. A preferred method for attaching the nucleic acids to a surface is by printing on glass plates, as is described generally by Schena *et al.*, 1995, Quantitative monitoring of gene expression patterns with a complementary DNA microarray, *Science* 270:467-470. This method is especially useful for preparing microarrays of cDNA. *See also* DeRisi *et al.*, 1996, Use of a cDNA microarray to analyze gene expression patterns in human cancer, *Nature Genetics* 14:457-460; Shalon *et al.*, 1996, A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization, *Genome Res.* 6:639-645; and Schena *et al.*, 1995, Parallel human genome analysis; microarray-based expression of 1000 genes, *Proc. Natl. Acad. Sci. USA* 93:10539-11286.

A second preferred method for making microarrays is by making high-density oligonucleotide arrays. Techniques are known for producing arrays containing thousands of oligonucleotides complementary to defined sequences, at defined locations on a surface using photolithographic techniques for synthesis *in situ* (see, Fodor *et al.*, 1991, Light-directed spatially addressable parallel chemical synthesis, *Science* 251:767-773; Pease *et al.*, 1994, Light-directed oligonucleotide arrays for rapid DNA sequence analysis, *Proc. Natl. Acad. Sci. USA* 91:5022-5026; Lockhart *et al.*, 1996, Expression monitoring by hybridization to high-density oligonucleotide arrays, *Nature Biotech* 14:1675; U.S. Patent Nos. 5,578,832; 5,556,752; and 5,510,270, each of which is incorporated by reference in its entirety for all purposes) or other methods for rapid synthesis and deposition of defined oligonucleotides (Blanchard *et al.*, 1996, High-Density Oligonucleotide arrays, *Biosensors & Bioelectronics* 11: 687-90). When these methods are used, oligonucleotides (*e.g.*, 20-mers) of known sequence are synthesized directly on a surface such as a derivatized glass slide. Usually, the array produced contains multiple probes against each target transcript. Oligonucleotide probes can be chosen to detect alternatively spliced mRNAs or to serve as various type of control.

5 Another preferred method of making microarrays is by use of an inkjet printing process to synthesize oligonucleotides directly on a solid phase, as described, *e.g.*, in co-pending U.S. patent application Serial No. 09/008,120 filed on January 16, 1998, by Blanchard entitled "Chemical Synthesis Using Solvent Microdroplets", which is
10 incorporated by reference herein in its entirety.

Other methods for making microarrays, *e.g.*, by masking (Maskos and Southern, 1992, *Nuc. Acids Res.* 20:1679-1684), may also be used. In principal, any type of array, for example, dot blots on a nylon hybridization membrane (*see* Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual* (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold
15 Spring Harbor, New York, 1989), could be used, although, as will be recognized by those of skill in the art, very small arrays will be preferred because hybridization volumes will be smaller.

In a particularly preferred embodiment, micorarrays used in the invention are manufactured by means of an ink jet printing device for oligonucleotide synthesis, *e.g.*,
20 using the methods and systems described by Blanchard in International Patent Publication No. WO 98/41531, published on September 24, 1998; Blanchard *et al.*, 1996, *Biosensors and Bioelectronics* 11:687-690; Blanchard, 1998, in *Synthetic DNA Arrays in Genetic Engineering*, Vol. 20, J.K. Setlow, ed., Plenum Press, New York at pages 111-123. Specifically, the oligonucleotide probes in such microarrays are preferably synthesized by
25 serially depositing individual nucleotides for each probe sequence in an array of "microdroplets" of a high surface tension solvent such a propylene carbonate. The microdroplets have small volumes (*e.g.*, 100 pL or less, more preferably 50 pL or less) and are separated from each other on the microarray (*e.g.*, by hydrophobic domains) to form circular surface tension wells which define the locations of the array elements (*i.e.*, the
30 different probes).

5.7.1.3. TARGET POLYNUCLEOTIDE MOLECULES

Methods for preparing total and poly(A)+ RNA are well known and are described
40 generally in Sambrook *et al.*, *supra*. In one embodiment, RNA is extracted from cells of the various types of interest in this invention using guanidinium thiocyanate lysis followed by CsCl centrifugation (Chirgwin *et al.*, 1979, *Biochemistry* 18:5294-5299). Poly(A)+ RNA is selected by selection with oligo-dT cellulose (*see* Sambrook *et al.*, *supra*). Cells of interest
45 include wild-type cells, drug-exposed wild-type cells, modified cells, and drug-exposed modified cells.

35 Labeled cDNA is prepared from mRNA by oligo dT-primed or random-primed reverse transcription, both of which are well known in the art (*see, e.g.*, Klug and Berger,

1987, Methods Enzymol. 152:316-325). Reverse transcription may be carried out in the presence of a dNTP conjugated to a detectable label, most preferably a fluorescently labeled dNTP. Alternatively, isolated mRNA can be converted to labeled antisense RNA synthesized by in vitro transcription of double-stranded cDNA in the presence of labeled dNTPs (Lockhart *et al.*, 1996, Expression monitoring by hybridization to high-density oligonucleotide arrays, Nature Biotech. 14:1675, which is incorporated by reference in its entirety for all purposes). In alternative embodiments, the cDNA or RNA probe can be synthesized in the absence of detectable label and may be labeled subsequently, *e.g.*, by incorporating biotinylated dNTPs or rNTP, or some similar means (*e.g.*, photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (*e.g.*, phycoerythrin-conjugated streptavidin) or the equivalent.

When fluorescently-labeled probes are used, many suitable fluorophores are known, including fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others (*see, e.g.*, Kricka, 1992, Nonisotopic DNA Probe Techniques, Academic Press San Diego, CA). It will be appreciated that pairs of fluorophores are chosen that have distinct emission spectra so that they can be easily distinguished.

In another embodiment, a label other than a fluorescent label is used. For example, a radioactive label, or a pair of radioactive labels with distinct emission spectra, can be used (*see Zhao et al.*, 1995, High density cDNA filter analysis: a novel approach for large-scale, quantitative analysis of gene expression, Gene 156:207; Pietu *et al.*, 1996, Novel gene transcripts preferentially expressed in human muscles revealed by quantitative hybridization of a high density cDNA array, Genome Res. 6:492). However, because of scattering of radioactive particles, and the consequent requirement for widely spaced binding sites, use of radioisotopes is a less-preferred embodiment.

In one embodiment, labeled cDNA is synthesized by incubating a mixture containing 0.5 mM dGTP, dATP and dCTP plus 0.1 mM dTTP plus fluorescent deoxyribonucleotides (*e.g.*, 0.1 mM Rhodamine 110 UTP (Perkin Elmer Cetus) or 0.1 mM Cy3 dUTP (Amersham)) with reverse transcriptase (*e.g.*, SuperScript™ II, LTI Inc.) at 42° C for 60 min.

5.7.1.4. HYBRIDIZATION TO MICROARRAYS

Nucleic acid hybridization and wash conditions are optimally chosen so that the probe "specifically binds" or "specifically hybridizes" to a specific array site, *i.e.*, the probe hybridizes, duplexes or binds to a sequence array site with a complementary nucleic acid sequence but does not hybridize to a site with a non-complementary nucleic acid sequence. As used herein, one polynucleotide sequence is considered complementary to another when,

5 if the shorter of the polynucleotides is less than or equal to 25 bases, there are no mismatches using standard base-pairing rules or, if the shorter of the polynucleotides is longer than 25 bases, there is no more than a 5% mismatch. Preferably, the polynucleotides are perfectly complementary (no mismatches). It can easily be demonstrated that specific
10 hybridization conditions result in specific hybridization by carrying out a hybridization assay including negative controls (*see, e.g., Shalon et al., supra, and Chee et al., supra*).

Optimal hybridization conditions will depend on the length (*e.g., oligomer versus polynucleotide greater than 200 bases*) and type (*e.g., RNA, DNA, PNA*) of labeled probe and immobilized polynucleotide or oligonucleotide. General parameters for specific (*i.e.,*
15 stringent) hybridization conditions for nucleic acids are described in Sambrook *et al., supra*, and in Ausubel *et al., 1987, Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York. When the cDNA microarrays of Schena *et al.* are used,
20 typical hybridization conditions are hybridization in 5 X SSC plus 0.2% SDS at 65° C for 4 hours followed by washes at 25° C in low stringency wash buffer (1 X SSC plus 0.2% SDS)
15 followed by 10 minutes at 25° C in high stringency wash buffer (0.1 X SSC plus 0.2% SDS) (Shena *et al., 1996, Proc. Natl. Acad. Sci. USA, 93:10614*). Useful hybridization conditions are also provided in, *e.g., Tijessen, 1993, Hybridization With Nucleic Acid Probes*, Elsevier Science Publishers B.V. and Kricka, 1992, *Nonisotopic DNA Probe Techniques*, Academic Press San Diego, CA.

20 5.7.1.5. SIGNAL DETECTION AND DATA ANALYSIS

When fluorescently labeled probes are used, the fluorescence emissions at each site of a transcript array can be, preferably, detected by scanning confocal laser microscopy. In one embodiment, a separate scan, using the appropriate excitation line, is carried out for
35 each of the two fluorophores used. Alternatively, a laser can be used that allows simultaneous specimen illumination at wavelengths specific to the two fluorophores and emissions from the two fluorophores can be analyzed simultaneously (*see Shalon et al., 1996, A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization, Genome Research 6:639-645, which is incorporated by*
40 reference in its entirety for all purposes). In a preferred embodiment, the arrays are scanned with a laser fluorescent scanner with a computer controlled X-Y stage and a microscope objective. Sequential excitation of the two fluorophores is achieved with a multi-line, mixed gas laser and the emitted light is split by wavelength and detected with two photomultiplier tubes. Fluorescence laser scanning devices are described in Schena *et al., 1996, Genome*
45 Res. 6:639-645 and in other references cited herein. Alternatively, the fiber-optic bundle
35

described by Ferguson *et al.*, 1996, Nature Biotech. 14:1681-1684, may be used to monitor mRNA abundance levels at a large number of sites simultaneously.

Signals are recorded and, in a preferred embodiment, analyzed by computer, *e.g.*, using a 12 bit analog to digital board. In one embodiment the scanned image is despeckled using a graphics program (*e.g.*, Hijaak Graphics Suite) and then analyzed using an image gridding program that creates a spreadsheet of the average hybridization at each wavelength at each site. If necessary, an experimentally determined correction for "cross talk" (or overlap) between the channels for the two fluors may be made. For any particular hybridization site on the transcript array, a ratio of the emission of the two fluorophores can be calculated. The ratio is independent of the absolute expression level of the cognate gene, but is useful for genes whose expression is significantly modulated by drug administration, gene deletion, or any other tested event.

According to the method of the invention, the relative abundance of an mRNA in two biological samples is scored as a perturbation and its magnitude determined (*i.e.*, the abundance is different in the two sources of mRNA tested), or as not perturbed (*i.e.*, the relative abundance is the same). In various embodiments, a difference between the two sources of RNA of at least a factor of about 25% (RNA from one source is 25% more abundant in one source than the other source), more usually about 50%, even more often by a factor of about 2 (twice as abundant), 3 (three times as abundant) or 5 (five times as abundant) is scored as a perturbation.

Preferably, in addition to identifying a perturbation as positive or negative, it is advantageous to determine the magnitude of the perturbation. This can be carried out, as noted above, by calculating the ratio of the emission of the two fluorophores used for differential labeling, or by analogous methods that will be readily apparent to those of skill in the art.

5.7.2. PATHWAY RESPONSE AND GENESETS

In one embodiment of the present invention, genesets are determined by observing the gene expression response of perturbation to a particular pathway. In one embodiment of the invention, transcript arrays reflecting the transcriptional state of a biological sample of interest are made by hybridizing a mixture of two differently labeled probes each corresponding (*i.e.*, complementary) to the mRNA of a different sample of interest, to the microarray. According to the present invention, the two samples are of the same type, *i.e.*, of the same species and strain, but may differ genetically at a small number (*e.g.*, one, two, three, or five, preferably one) of loci. Alternatively, they are isogenic and differ in their

5 environmental history (e.g., exposed to a drug versus not exposed). The genes whose expression are highly correlated may belong to a geneset.

In one aspect of the invention, gene expression change in response to a large number of perturbations is used to construct a clustering tree for the purpose of defining genesets.

10 5 Preferably, the perturbations should target different pathways. In order to measure expression responses to the pathway perturbation, biological samples are subjected to graded perturbations to pathways of interest. The samples exposed to the perturbation and samples not exposed to the perturbation are used to construct transcript arrays, which are measured to find the mRNAs with modified expression and the degree of modification due to exposure to
15 the perturbation. Thereby, the perturbation-response relationship is obtained.

The density of levels of the graded drug exposure and graded perturbation control parameter is governed by the sharpness and structure in the individual gene responses - the steeper the steepest part of the response, the denser the levels needed to properly resolve the response.

15 20 Further, it is preferable in order to reduce experimental error to reverse the fluorescent labels in two-color differential hybridization experiments to reduce biases peculiar to individual genes or array spot locations. In other words, it is preferable to first measure gene expression with one labeling (e.g., labeling perturbed cells with a first fluorochrome and unperturbed cells with a second fluorochrome) of the mRNA from the two
25 20 cells being measured, and then to measure gene expression from the two cells with reversed labeling (e.g., labeling perturbed cells with the second fluorochrome and unperturbed cells with the first fluorochrome). Multiple measurements over exposure levels and perturbation control parameter levels provide additional experimental error control. With adequate sampling a trade-off may be made when choosing the width of the spline function S used to
30 35 interpolate response data between averaging of errors and loss of structure in the response functions.

40 5.7.3. MEASUREMENT OF GRADED PERTURBATION RESPONSE DATA

To measure graded response data, the cells are exposed to graded levels of the drug,
30 drug candidate of interest or grade strength of other perturbation. When the cells are grown in vitro, the compound is usually added to their nutrient medium. In the case of yeast, it is preferable to harvest the yeast in early log phase, since expression patterns are relatively
45 insensitive to time of harvest at that time. Several levels of the drug or other compounds are added. The particular level employed depends on the particular characteristics of the drug,
35 but usually will be between about 1 ng/ml and 100 mg/ml. In some cases a drug will be solubilized in a solvent such as DMSO.

5 The cells exposed to the drug and cells not exposed to the drug are used to construct transcript arrays, which are measured to find the mRNAs with altered expression due to exposure to the drug. Thereby, the drug response is obtained.

10 Similarly for measurements of pathway responses, it is preferable also for drug responses, in the case of two-color differential hybridization, to measure also with reversed labeling. Also, it is preferable that the levels of drug exposure used proved sufficient resolution (e.g., by using approximately 10 levels of drug exposure) of rapidly changing regions of the drug response.

10 5.7.4. OTHER METHODS OF TRANSCRIPTIONAL STATE MEASUREMENT

20 The transcriptional state of a cell may be measured by other gene expression technologies known in the art. Several such technologies produce pools of restriction fragments of limited complexity for electrophoretic analysis, such as methods combining double restriction enzyme digestion with phasing primers (*see, e.g.*, European Patent O 15 534858 A1, filed September 24, 1992, by Zabeau et al.), or methods selecting restriction fragments with sites closest to a defined mRNA end (*see, e.g.*, Prashar et al., 1996, Proc. 25 Natl. Acad. Sci. USA 93:659-663). Other methods statistically sample cDNA pools, such as by sequencing sufficient bases (e.g., 20-50 bases) in each of multiple cDNAs to identify each cDNA, or by sequencing short tags (e.g., 9-10 bases) which are generated at known 30 positions relative to a defined mRNA end (*see, e.g.*, Velculescu, 1995, Science 270:484-487).

35 5.7.5. MEASUREMENT OF OTHER ASPECTS OF BIOLOGICAL STATE

40 In various embodiments of the present invention, aspects of the biological state other than the transcriptional state, such as the translational state, the activity state, or mixed 25 aspects can be measured in order to obtain drug and pathway responses. Details of these embodiments are described in this section.

40 5.7.5.1. EMBODIMENTS BASED ON TRANSLATIONAL STATE MEASUREMENTS

30 Measurement of the translational state may be performed according to several methods. For example, whole genome monitoring of protein (*i.e.*, the "proteome," Goffeau 45 *et al.*, supra) can be carried out by constructing a microarray in which binding sites comprise immobilized, preferably monoclonal, antibodies specific to a plurality of protein species encoded by the cell genome. Preferably, antibodies are present for a substantial fraction of 35 the encoded proteins, or at least for those proteins relevant to the action of a drug of interest. Methods for making monoclonal antibodies are well known (*see, e.g.*, Harlow and Lane,

5 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor, New York, which is incorporated in its entirety for all purposes). In a preferred embodiment, monoclonal antibodies are raised against synthetic peptide fragments designed based on genomic
10 sequence of the cell. With such an antibody array, proteins from the cell are contacted to the array and their binding is assayed with assays known in the art.

Alternatively, proteins can be separated by two-dimensional gel electrophoresis systems. Two-dimensional gel electrophoresis is well-known in the art and typically involves iso-electric focusing along a first dimension followed by SDS-PAGE
15 electrophoresis along a second dimension. See, e.g., Hames *et al.*, 1990, *Gel Electrophoresis of Proteins: A Practical Approach*, IRL Press, New York; Shevchenko *et al.*, 1996, *Proc. Nat'l Acad. Sci. USA* 93:1440-1445; Sagliocco *et al.*, 1996, *Yeast* 12:1519-1533; Lander, 1996, *Science* 274:536-539. The resulting electropherograms can be analyzed by numerous
20 techniques, including mass spectrometric techniques, western blotting and immunoblot analysis using polyclonal and monoclonal antibodies, and internal and N-terminal micro-sequencing. Using these techniques, it is possible to identify a substantial fraction of all the
25 proteins produced under given physiological conditions, including in cells (e.g., in yeast) exposed to a drug, or in cells modified by, e.g., deletion or over-expression of a specific gene.

30 5.7.5.2. EMBODIMENTS BASED ON OTHER ASPECTS OF THE BIOLOGICAL STATE

Even though methods of this invention are illustrated by embodiments involving gene expression profiles, the methods of the invention are applicable to any cellular
35 constituent that can be monitored.

25 In particular, where activities of proteins relevant to the characterization of a perturbation, such as drug action, can be measured, embodiments of this invention can be based on such measurements. Activity measurements can be performed by any functional, biochemical, or physical means appropriate to the particular activity being characterized.
40 Where the activity involves a chemical transformation, the cellular protein can be contacted with the natural substrate(s), and the rate of transformation measured. Where the activity involves association in multimeric units, for example association of an activated DNA binding complex with DNA, the amount of associated protein or secondary consequences of
45 the association, such as amounts of mRNA transcribed, can be measured. Also, where only a functional activity is known, for example, as in cell cycle control, performance of the function can be observed. However known and measured, the changes in protein activities
35 form the response data analyzed by the foregoing methods of this invention.

5 In alternative and non-limiting embodiments, response data may be formed of mixed aspects of the biological state of a cell. Response data can be constructed from, e.g., changes in certain mRNA abundances, changes in certain protein abundances, and changes in certain protein activities.

10 5.8. METHOD FOR PROBING CELLULAR STATES

One aspect of the invention provides methods for the analysis of co-varying cellular constituents. The methods of this invention are also useful for the analysis of responses of a biological sample to perturbations designed to probe cellular state. This section provides 15 some illustrative methods for probing cellular states.

Methods for targeted perturbation of cellular states at various levels of a cell are increasingly widely known and applied in the art. Any such methods that are capable of specifically targeting and controllably modifying (e.g., either by a graded increase or activation or by a graded decrease or inhibition) specific cellular constituents (e.g., gene 20 expression, RNA concentrations, protein abundances, protein activities, or so forth) can be employed in performing cellular state perturbations. Controllable modifications of cellular constituents consequentially controllably perturb cellular states originating at the modified cellular constituents. Preferable modification methods are capable of individually targeting each of a plurality of cellular constituents and most preferably a substantial fraction of such 25 cellular constituents.

The following methods are exemplary of those that can be used to modify cellular constituents and thereby to produce cellular state perturbations which generate the cellular state responses used in the steps of the methods of this invention as previously described. This invention is adaptable to other methods for making controllable perturbations to 30 cellular states, and especially to cellular constituents from which cellular states originate.

Cellular state perturbations are preferably made in cells of cell types derived from any organism for which genomic or expressed sequence information is available and for which methods are available that permit controllable modification of the expression of specific genes. Genome sequencing is currently underway for several eukaryotic organisms, 35 including humans, nematodes, *Arabidopsis*, and flies. In a preferred embodiment, the invention is carried out using a yeast, with *Saccharomyces cerevisiae* most preferred because the sequence of the entire genome of a *S. cerevisiae* strain has been determined. In addition, well-established methods are available for controllably modifying expression of yeast genes. A preferred strain of yeast is a *S. cerevisiae* strain for which yeast genomic sequence is 40 known, such as strain S288C or substantially isogenic derivatives of it (see, e.g., *Nature* 369, 371-8 (1994); *P.N.A.S.* 92:3809-13 (1995); *E.M.B.O. J.* 13:5795-5809 (1994), *Science* 45

265:2077-2082 (1994); *E.M.B.O. J.* 15:2031-49 (1996), all of which are incorporated herein. However, other strains may be used as well. Yeast strains are available from American Type Culture Collection, Manassas, Virginia. Standard techniques for manipulating yeast are described in C. Kaiser, S. Michaelis, & A. Mitchell, 1994, Methods in Yeast Genetics: A
Cold Spring Harbor Laboratory Course Manual, Cold Spring Harbor Laboratory Press, New York; and Sherman *et al.*, 1986, Methods in Yeast Genetics: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, both of which are incorporated by reference in their entirety and for all purposes.

The exemplary methods described in the following include use of titratable expression systems, use of transfection or viral transduction systems, direct modifications to RNA abundances or activities, direct modifications of protein abundances, and direct modification of protein activities including use of drugs (or chemical moieties in general) with specific known action.

5.8.1. TITRATABLE EXPRESSION SYSTEMS

Any of the several known titratable, or equivalently controllable, expression systems available for use in the budding yeast *Saccharomyces cerevisiae* are adaptable to this invention (Mumberg *et al.*, 1994, Regulatable promoter of *Saccharomyces cerevisiae*: comparison of transcriptional activity and their use for heterologous expression, Nucl. Acids Res. 22:5767-5768). Usually, gene expression is controlled by transcriptional controls, with the promoter of the gene to be controlled replaced on its chromosome by a controllable, exogenous promoter. The most commonly used controllable promoter in yeast is the GAL1 promoter (Johnston *et al.*, 1984, Sequences that regulate the divergent GAL1-GAL10 promoter in *Saccharomyces cerevisiae*, Mol Cell. Biol. 8:1440-1448). The GAL1 promoter is strongly repressed by the presence of glucose in the growth medium, and is gradually switched on in a graded manner to high levels of expression by the decreasing abundance of glucose and the presence of galactose. The GAL1 promoter usually allows a 5-100 fold range of expression control on a gene of interest.

Other frequently used promoter systems include the MET25 promoter (Kerjan *et al.*, 1986, Nucleotide sequence of the *Saccharomyces cerevisiae* MET25 gene, Nucl. Acids. Res. 14:7861-7871), which is induced by the absence of methionine in the growth medium, and the CUP1 promoter, which is induced by copper (Mascorro-Gallardo *et al.*, 1996, Construction of a CUP1 promoter-based vector to modulate gene expression in *Saccharomyces cerevisiae*, Gene 172:169-170). All of these promoter systems are controllable in that gene expression can be incrementally controlled by incremental changes in the abundances of a controlling moiety in the growth medium.

5 One disadvantage of the above listed expression systems is that control of promoter activity (effected by, *e.g.*, changes in carbon source, removal of certain amino acids), often causes other changes in cellular physiology which independently alter the expression levels of other genes. A recently developed system for yeast, the Tet system, alleviates this
10 problem to a large extent (Gari *et al.*, 1997, A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in *Saccharomyces cerevisiae*, *Yeast* 13:837-848). The Tet promoter, adopted from mammalian expression systems (Gossen *et al.*, 1995, Transcriptional activation by tetracyclines in mammalian cells, *Proc. Nat. Acad. Sci. USA* 89:5547-5551) is modulated by the concentration of the antibiotic tetracycline or the
15 structurally related compound doxycycline. Thus, in the absence of doxycycline, the promoter induces a high level of expression, and the addition of increasing levels of doxycycline causes increased repression of promoter activity. Intermediate levels of gene expression can be achieved in the steady state by addition of intermediate levels of drug. Furthermore, levels of doxycycline that give maximal repression of promoter activity (10
20 micrograms/ml) have no significant effect on the growth rate on wild type yeast cells (Gari *et al.*, 1997, A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in *Saccharomyces cerevisiae*, *Yeast* 13:837-848).

In mammalian cells, several means of titrating expression of genes are available (Spencer, 1996, Creating conditional mutations in mammals, *Trends Genet.* 12:181-187).
20 As mentioned above, the Tet system is widely used, both in its original form, the "forward" system, in which addition of doxycycline represses transcription, and in the newer "reverse" system, in which doxycycline addition stimulates transcription (Gossen *et al.*, 1995, *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Hoffmann *et al.*, 1997, *Nucl. Acids. Res.* 25:1078-1079; Hofmann *et al.*, 1996, *Proc. Natl. Acad. Sci. USA* 83:5185-5190; Paulus *et al.*, 1996,
35 *Journal of Virology* 70:62-67). Another commonly used controllable promoter system in mammalian cells is the ecdysone-inducible system developed by Evans and colleagues (No *et al.*, 1996, Ecdysone-inducible gene expression in mammalian cells and transgenic mice, *Proc. Nat. Acad. Sci. USA* 93:3346-3351), where expression is controlled by the level of muristerone added to the cultured cells. Finally, expression can be modulated using the
40 "chemical-induced dimerization" (CID) system developed by Schreiber, Crabtree, and colleagues (Belshaw *et al.*, 1996, Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins, *Proc. Nat. Acad. Sci. USA* 93:4604-4607; Spencer, 1996, Creating conditional mutations in mammals, *Trends Genet.* 12:181-187) and similar systems in yeast. In this system, the gene of interest is put
45 under the control of the CID-responsive promoter, and transfected into cells expressing two
35 different hybrid proteins, one comprised of a DNA-binding domain fused to FKBP12, which

5 binds FK506. The other hybrid protein contains a transcriptional activation domain also
fused to FKBP12. The CID inducing molecule is FK1012, a homodimeric version of FK506
that is able to bind simultaneously both the DNA binding and transcriptional activating
10 hybrid proteins. In the graded presence of FK1012, graded transcription of the controlled
5 gene is activated.

For each of the mammalian expression systems described above, as is widely known
to those of skill in the art, the gene of interest is put under the control of the controllable
15 promoter, and a plasmid harboring this construct along with an antibiotic resistance gene is
transfected into cultured mammalian cells. In general, the plasmid DNA integrates into the
10 genome, and drug resistant colonies are selected and screened for appropriate expression of
the regulated gene. Alternatively, the regulated gene can be inserted into an episomal
plasmid such as pCEP4 (Invitrogen, Inc.), which contains components of the Epstein-Barr
20 virus necessary for plasmid replication.

In a preferred embodiment, titratable expression systems, such as the ones described
15 above, are introduced for use into cells or organisms lacking the corresponding endogenous
gene and/or gene activity, *e.g.*, organisms in which the endogenous gene has been disrupted
or deleted. Methods for producing such "knock outs" are well known to those of skill in the
25 art, see *e.g.*, Pettitt *et al.*, 1996, Development 122:4149-4157; Spradling *et al.*, 1995, Proc.
Nat'l. Acad. Sci. USA, 92:10824-10830; Ramirez-Solis *et al.*, 1993, Methods Enzymol.
20 225:855-878; and Thomas *et al.*, 1987, Cell 51:503-512.

5.8.2. TRANSFECTION SYSTEMS FOR MAMMALIAN CELLS

Transfection or viral transduction of target genes can introduce controllable
perturbations in biological cellular states in mammalian cells. Preferably, transfection or
35 transduction of a target gene can be used with cells that do not naturally express the target
gene of interest. Such non-expressing cells can be derived from a tissue not normally
expressing the target gene or the target gene can be specifically mutated in the cell. The
40 target gene of interest can be cloned into one of many mammalian expression plasmids, for
example, the pcDNA3.1 +/- system (Invitrogen, Inc.) or retroviral vectors, and introduced
30 into the non-expressing host cells. Transfected or transduced cells expressing the target gene
may be isolated by selection for a drug resistance marker encoded by the expression vector.
The level of gene transcription is monotonically related to the transfection dosage. In this
45 way, the effects of varying levels of the target gene may be investigated.

A particular example of the use of this method is the search for drugs that target the
35 src-family protein tyrosine kinase, lck, a key component of the T cell receptor activation
cellular state (Anderson *et al.*, 1994, Involvement of the protein tyrosine kinase p56 (lck) in

5 T cell signaling and thymocyte development, Adv. Immunol. 56:171-178). Inhibitors of this enzyme are of interest as potential immunosuppressive drugs (Hanke, 1996, Discovery of a Novel, Potent, and src family-selective tyrosine kinase inhibitor, J. Biol Chem 271:695-701).
10 A specific mutant of the Jurkat T cell line (JCaM1) is available that does not express lck kinase (Straus *et al.*, 1992, Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor, Cell 70:585-593). Therefore, introduction of the lck gene into JCaM1 by transfection or transduction permits specific
15 perturbation of cellular states of T cell activation regulated by the lck kinase. The efficiency of transfection or transduction, and thus the level of perturbation, is dose related. The method is generally useful for providing perturbations of gene expression or protein
20 abundances in cells not normally expressing the genes to be perturbed.

20 5.8.3. METHODS OF MODIFYING RNA ABUNDANCES OR ACTIVITIES

Methods of modifying RNA abundances and activities currently fall within three
15 classes, ribozymes, antisense species, and RNA aptamers (Good *et al.*, 1997, Gene Therapy 4: 45-54). Controllable application or exposure of a cell to these entities permits
25 controllable perturbation of RNA abundances.

Ribozymes are RNAs which are capable of catalyzing RNA cleavage reactions. (Cech, 1987, Science 236:1532-1539; PCT International Publication WO 90/11364,
30 published October 4, 1990; Sarver *et al.*, 1990, Science 247: 1222-1225). "Hairpin" and "hammerhead" RNA ribozymes can be designed to specifically cleave a particular target mRNA. Rules have been established for the design of short RNA molecules with ribozyme activity, which are capable of cleaving other RNA molecules in a highly sequence specific way and can be targeted to virtually all kinds of RNA. (Haseloff *et al.*, 1988, Nature
35 334:585-591; Koizumi *et al.*, 1988, FEBS Lett., 228:228-230; Koizumi *et al.*, 1988, FEBS Lett., 239:285-288). Ribozyme methods involve exposing a cell to, inducing expression in a cell, etc. of such small RNA ribozyme molecules. (Grassi and Marini, 1996, Annals of
40 Medicine 28: 499-510; Gibson, 1996, Cancer and Metastasis Reviews 15: 287-299).

Ribozymes can be routinely expressed *in vivo* in sufficient number to be catalytically
30 effective in cleaving mRNA, and thereby modifying mRNA abundances in a cell. (Cotten *et al.*, 1989, Ribozyme mediated destruction of RNA in vivo, The EMBO J. 8:3861-3866). In particular, a ribozyme coding DNA sequence, designed according to the previous rules and synthesized, for example, by standard phosphoramidite chemistry, can be ligated into a
45 restriction enzyme site in the anticodon stem and loop of a gene encoding a tRNA, which can then be transformed into and expressed in a cell of interest by methods routine in the art.
50 Preferably, an inducible promoter (*e.g.*, a glucocorticoid or a tetracycline response element)

5 is also introduced into this construct so that ribozyme expression can be selectively controlled. tDNA genes (*i.e.*, genes encoding tRNAs) are useful in this application because of their small size, high rate of transcription, and ubiquitous expression in different kinds of tissues. Therefore, ribozymes can be routinely designed to cleave virtually any mRNA
10 sequence, and a cell can be routinely transformed with DNA coding for such ribozyme sequences such that a controllable and catalytically effective amount of the ribozyme is expressed. Accordingly the abundance of virtually any RNA species in a cell can be perturbed.

15 In another embodiment, activity of a target RNA (preferable mRNA) species, specifically its rate of translation, can be controllably inhibited by the controllable application of antisense nucleic acids. An "antisense" nucleic acid as used herein refers to a nucleic acid capable of hybridizing to a sequence-specific (*e.g.*, non-poly A) portion of the target RNA, for example its translation initiation region, by virtue of some sequence complementarity to a coding and/or non-coding region. The antisense nucleic acids of the
20 invention can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered in a controllable manner to a cell or which can be produced intracellularly by transcription of exogenous, introduced sequences in controllable quantities sufficient to perturb translation of the target RNA.

25 Preferably, antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 200 oligonucleotides). In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides. The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The
30 oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger *et al.*, 1989, Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre *et al.*, 1987, Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO 88/09810, published December 15, 1988), hybridization-triggered
35 cleavage agents (*see, e.g.*, Krol *et al.*, 1988, BioTechniques 6: 958-976) or intercalating agents (*see, e.g.*, Zon, 1988, Pharm. Res. 5: 539-549).

40 In a preferred aspect of the invention, an antisense oligonucleotide is provided, preferably as single-stranded DNA. The oligonucleotide may be modified at any position on its structure with constituents generally known in the art.

45 The antisense oligonucleotides may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil,
50

5 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine,
 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,
 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine,
 10 N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,
 5 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine,
 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-
 D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-
 15 isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,
 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-
 20 5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-
 3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

In another embodiment, the oligonucleotide comprises at least one modified sugar
 moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose,
 xylulose, and hexose.

15 In yet another embodiment, the oligonucleotide comprises at least one modified
 phosphate backbone selected from the group consisting of a phosphorothioate, a
 25 phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a
 methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the oligonucleotide is a 2- α -anomeric oligonucleotide.

20 An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary
 RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier *et*
al., 1987, Nucl. Acids Res. 15: 6625-6641).

The oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide,
 35 hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage
 25 agent, etc.

The antisense nucleic acids of the invention comprise a sequence complementary to
 at least a portion of a target RNA species. However, absolute complementarity, although
 40 preferred, is not required. A sequence "complementary to at least a portion of an RNA," as
 referred to herein, means a sequence having sufficient complementarity to be able to
 30 hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense
 nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation
 45 may be assayed. The ability to hybridize will depend on both the degree of complementarity
 and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic
 acid, the more base mismatches with a target RNA it may contain and still form a stable
 35 duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree
 50 of mismatch by use of standard procedures to determine the melting point of the hybridized

5 complex. The amount of antisense nucleic acid that will be effective in the inhibiting translation of the target RNA can be determined by standard assay techniques.

10 Oligonucleotides of the invention may be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides
5 may be synthesized by the method of Stein *et al.* (1988, Nucl. Acids Res. 16: 3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. 85: 7448-7451), etc. In
15 another embodiment, the oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. 15: 6131-6148), or a chimeric RNA-DNA analog (Inoue *et al.*, 1987, FEBS Lett. 215: 327-330).

20 The synthesized antisense oligonucleotides can then be administered to a cell in a controlled manner. For example, the antisense oligonucleotides can be placed in the growth environment of the cell at controlled levels where they may be taken up by the cell. The
15 uptake of the antisense oligonucleotides can be assisted by use of methods well known in the art.

25 In an alternative embodiment, the antisense nucleic acids of the invention are controllably expressed intracellularly by transcription from an exogenous sequence. For example, a vector can be introduced *in vivo* such that it is taken up by a cell, within which
30 cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed
35 by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.

40 Expression of the sequences encoding the antisense RNAs can be by any promoter known in the art to act in a cell of interest. Such promoters can be inducible or constitutive. Most preferably, promoters are controllable or inducible by the administration of an exogenous moiety in order to achieve controlled expression of the antisense oligonucleotide. Such
30 controllable promoters include the Tet promoter. Less preferably usable promoters for mammalian cells include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290: 304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, 1980, Cell 22: 787-797), the herpes
45 thymidine kinase promoter (Wagner *et al.*, 1981, Proc. Natl. Acad. Sci. U.S.A. 78: 1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, 1982, Nature 296: 39-42), etc.

Therefore, antisense nucleic acids can be routinely designed to target virtually any mRNA sequence, and a cell can be routinely transformed with or exposed to nucleic acids coding for such antisense sequences such that an effective and controllable amount of the antisense nucleic acid is expressed. Accordingly the translation of virtually any RNA species in a cell can be controllably perturbed.

Finally, in a further embodiment, RNA aptamers can be introduced into or expressed in a cell. RNA aptamers are specific RNA ligands for proteins, such as for Tat and Rev RNA (Good *et al.*, 1997, Gene Therapy 4: 45-54) that can specifically inhibit their translation.

5.8.4. METHODS OF MODIFYING PROTEIN ABUNDANCES

Methods of modifying protein abundances include, *inter alia*, those altering protein degradation rates and those using antibodies (which bind to proteins affecting abundances of activities of native target protein species). Increasing (or decreasing) the degradation rates of a protein species decreases (or increases) the abundance of that species. Methods for controllably increasing the degradation rate of a target protein in response to elevated temperature and/or exposure to a particular drug, which are known in the art, can be employed in this invention. For example, one such method employs a heat-inducible or drug-inducible N-terminal degron, which is an N-terminal protein fragment that exposes a degradation signal promoting rapid protein degradation at a higher temperature (*e.g.*, 37° C) and which is hidden to prevent rapid degradation at a lower temperature (*e.g.*, 23° C) (Dohmen *et. al*, 1994, Science 263:1273-1276). Such an exemplary degron is Arg-DHFR^u, a variant of murine dihydrofolate reductase in which the N-terminal Val is replaced by Arg and the Pro at position 66 is replaced with Leu. According to this method, for example, a gene for a target protein, P, is replaced by standard gene targeting methods known in the art (Lodish *et al.*, 1995, Molecular Biology of the Cell, W.H. Freeman and Co., New York, especially chap 8) with a gene coding for the fusion protein Ub-Arg-DHFR^u-P ("Ub" stands for ubiquitin). The N-terminal ubiquitin is rapidly cleaved after translation exposing the N-terminal degron. At lower temperatures, lysines internal to Arg-DHFR^u are not exposed, ubiquitination of the fusion protein does not occur, degradation is slow, and active target protein levels are high. At higher temperatures (in the absence of methotrexate), lysines internal to Arg-DHFR^u are exposed, ubiquitination of the fusion protein occurs, degradation is rapid, and active target protein levels are low. Heat activation of degradation is controllably blocked by exposure methotrexate. This method is adaptable to other N-terminal degrees which are responsive to other inducing factors, such as drugs and temperature changes.

5 Target protein abundances and also, directly or indirectly, their activities can also be
decreased by (neutralizing) antibodies. By providing for controlled exposure to such
antibodies, protein abundances/activities can be controllably modified. For example,
10 antibodies to suitable epitopes on protein surfaces may decrease the abundance, and thereby
5 indirectly decrease the activity, of the wild-type active form of a target protein by
aggregating active forms into complexes with less or minimal activity as compared to the
wild-type unaggregated wild-type form. Alternately, antibodies may directly decrease
protein activity by, *e.g.*, interacting directly with active sites or by blocking access of
15 substrates to active sites. Conversely, in certain cases, (activating) antibodies may also
10 interact with proteins and their active sites to increase resulting activity. In either case,
antibodies (of the various types to be described) can be raised against specific protein
species (by the methods to be described) and their effects screened. The effects of the
20 antibodies can be assayed and suitable antibodies selected that raise or lower the target
protein species concentration and/or activity. Such assays involve introducing antibodies
15 into a cell (see below), and assaying the concentration of the wild-type amount or activities
of the target protein by standard means (such as immunoassays) known in the art. The net
25 activity of the wild-type form can be assayed by assay means appropriate to the known
activity of the target protein.

Antibodies can be introduced into cells in numerous fashions, including, for
20 example, microinjection of antibodies into a cell (Morgan *et al.*, 1988, Immunology Today
9:84-86) or transforming hybridoma mRNA encoding a desired antibody into a cell (Burke
30 *et al.*, 1984, Cell 36:847-858). In a further technique, recombinant antibodies can be
engineering and ectopically expressed in a wide variety of non-lymphoid cell types to bind
to target proteins as well as to block target protein activities (Biocca *et al.*, 1995, Trends in
35 Cell Biology 5:248-252). Preferably, expression of the antibody is under control of a
controllable promoter, such as the Tet promoter. A first step is the selection of a particular
monoclonal antibody with appropriate specificity to the target protein (see below). Then
40 sequences encoding the variable regions of the selected antibody can be cloned into various
engineered antibody formats, including, for example, whole antibody, Fab fragments, Fv
30 fragments, single chain Fv fragments (V_H and V_L regions united by a peptide linker) ("ScFv"
fragments), diabodies (two associated ScFv fragments with different specificities), and so
forth (Hayden *et al.*, 1997, Current Opinion in Immunology 9:210-212). Intracellularly
45 expressed antibodies of the various formats can be targeted into cellular compartments (*e.g.*,
the cytoplasm, the nucleus, the mitochondria, etc.) by expressing them as fusions with the
35 various known intracellular leader sequences (Bradbury *et al.*, 1995, Antibody Engineering

5 (vol. 2) (Borrebaeck ed.), pp 295-361, IRL Press). In particular, the ScFv format appears to be particularly suitable for cytoplasmic targeting.

10 Antibody types include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Various procedures known in the art may be used for the production of polyclonal antibodies to a target protein. For production of the antibody, various host animals can be immunized by injection with the target protein, such host animals include, but are not limited to, rabbits, mice, rats, etc. Various adjuvants can be used to increase the immunological response, depending on the host species, and include, but are not limited to, Freund's (complete and incomplete), 15 mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, and potentially useful human adjuvants such as bacillus Calmette-Guerin (BCG) and corynebacterium parvum.

20 For preparation of monoclonal antibodies directed towards a target protein, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. Such techniques include, but are not restricted to, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256: 495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, 1983, Immunology Today 4: 72), and the EBV hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 25 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80: 2026-2030), or by transforming human B cells with EBV virus *in vitro* (Cole *et al.*, 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, Proc. Natl. Acad. Sci. USA 81: 6851-6855; Neuberger *et al.*, 1984, Nature 312:604-608; Takeda *et al.*, 1985, Nature 314: 452-454) by splicing the genes from a mouse antibody molecule specific for the target protein together with genes from a human antibody 30 molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

45 Additionally, where monoclonal antibodies are advantageous, they can be alternatively selected from large antibody libraries using the techniques of phage display (Marks *et al.*, 1992, J. Biol. Chem. 267:16007-16010). Using this technique, libraries of up to 10^{12} different antibodies have been expressed on the surface of fd filamentous phage, 50 creating a "single pot" *in vitro* immune system of antibodies available for the selection of

5 monoclonal antibodies (Griffiths *et al.*, 1994, EMBO J. 13:3245-3260). Selection of
antibodies from such libraries can be done by techniques known in the art, including
10 contacting the phage to immobilized target protein, selecting and cloning phage bound to the
target, and subcloning the sequences encoding the antibody variable regions into an
5 appropriate vector expressing a desired antibody format.

According to the invention, techniques described for the production of single chain
antibodies (U.S. patent 4,946,778) can be adapted to produce single chain antibodies specific
15 to the target protein. An additional embodiment of the invention utilizes the techniques
described for the construction of Fab expression libraries (Huse *et al.*, 1989, Science 246:
10 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the
desired specificity for the target protein.

Antibody fragments that contain the idiotypes of the target protein can be generated
20 by techniques known in the art. For example, such fragments include, but are not limited to:
the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule;
15 the Fab' fragments that can be generated by reducing the disulfide bridges of the F(ab')₂
fragment, the Fab fragments that can be generated by treating the antibody molecule with
25 papain and a reducing agent, and Fv fragments.

In the production of antibodies, screening for the desired antibody can be
accomplished by techniques known in the art, *e.g.*, ELISA (enzyme-linked immunosorbent
30 assay). To select antibodies specific to a target protein, one may assay generated
hybridomas or a phage display antibody library for an antibody that binds to the target
protein.

35 5.8.5. METHODS OF MODIFYING PROTEIN ACTIVITIES

25 Methods of directly modifying protein activities include, *inter alia*, dominant
negative mutations, specific drugs (used in the sense of this application) or chemical
moieties generally, and also the use of antibodies, as previously discussed.

Dominant negative mutations are mutations to endogenous genes or mutant
40 exogenous genes that when expressed in a cell disrupt the activity of a targeted protein
species. Depending on the structure and activity of the targeted protein, general rules exist
30 that guide the selection of an appropriate strategy for constructing dominant negative
mutations that disrupt activity of that target (Hershkowitz, 1987, Nature 329:219-222). In
45 the case of active monomeric forms, over expression of an inactive form can cause
competition for natural substrates or ligands sufficient to significantly reduce net activity of
35 the target protein. Such over expression can be achieved by, for example, associating a
promoter, preferably a controllable or inducible promoter, of increased activity with the
50

mutant gene. Alternatively, changes to active site residues can be made so that a virtually irreversible association occurs with the target ligand. Such can be achieved with certain tyrosine kinases by careful replacement of active site serine residues (Perlmutter *et al.*, 1996, Current Opinion in Immunology 8:285-290).

In the case of active multimeric forms, several strategies can guide selection of a dominant negative mutant. Multimeric activity can be controllably decreased by expression of genes coding exogenous protein fragments that bind to multimeric association domains and prevent multimer formation. Alternatively, controllable over expression of an inactive protein unit of a particular type can tie up wild-type active units in inactive multimers, and thereby decrease multimeric activity (Nocka *et al.*, 1990, The EMBO J. 9:1805-1813). For example, in the case of dimeric DNA binding proteins, the DNA binding domain can be deleted from the DNA binding unit, or the activation domain deleted from the activation unit. Also, in this case, the DNA binding domain unit can be expressed without the domain causing association with the activation unit. Thereby, DNA binding sites are tied up without any possible activation of expression. In the case where a particular type of unit normally undergoes a conformational change during activity, expression of a rigid unit can inactivate resultant complexes. For a further example, proteins involved in cellular mechanisms, such as cellular motility, the mitotic process, cellular architecture, and so forth, are typically composed of associations of many subunits of a few types. These structures are often highly sensitive to disruption by inclusion of a few monomeric units with structural defects. Such mutant monomers disrupt the relevant protein activities and can be controllably expressed in a cell.

In addition to dominant negative mutations, mutant target proteins that are sensitive to temperature (or other exogenous factors) can be found by mutagenesis and screening procedures that are well-known in the art.

Also, one of skill in the art will appreciate that expression of antibodies binding and inhibiting a target protein can be employed as another dominant negative strategy.

Finally, activities of certain target proteins can be controllably altered by exposure to exogenous drugs or ligands. In a preferable case, a drug is known that interacts with only one target protein in the cell and alters the activity of only that one target protein. Graded exposure of a cell to varying amounts of that drug thereby causes graded perturbations of cellular states originating at that protein. The alteration can be either a decrease or an increase of activity. Less preferably, a drug is known and used that alters the activity of only a few (*e.g.*, 2-5) target proteins with separate, distinguishable, and non-overlapping effects. Graded exposure to such a drug causes graded perturbations to the several cellular states originating at the target proteins.

6. EXAMPLES

The following examples are presented by way of illustration of the previously described invention and are not limiting of that description.

6.1. EXAMPLE 1: CLUSTERING GENESETS BY COREGULATION

This example illustrates one embodiment of the clustering method of the invention.

6.1.1. MATERIALS AND METHODS

Transcript measurement:

Yeast (*Saccharomyces cerevisiae*, Strain YPH499, *see*, Sikorski and Hieter, 1989, A system of shuttle vectors and yeast host strains designated for efficient manipulation of DNA in *Saccharomyces cerevisiae*, Genetics 122:19-27) cells were grown in YAPD at 30° C to an OD₆₀₀ of 1.0 (±0.2), and total RNA prepared by breaking cells in phenol/chloroform and 0.1% SDS by standard procedures (Ausubel *et al.*, 1995, Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience, New York, Ch. 13). Poly(A)⁺ RNA was selected by affinity chromatography on oligo-dT cellulose (New England Biolabs) essentially as described in Sambrook *et al.* (Molecular Cloning - A Laboratory Manual (2nd Ed.), Vol. 1, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). First strand cDNA synthesis was carried out with 2 µg poly(A)⁺ RNA and SuperScript™ II reverse transcriptase (Gibco-BRL) according to the manufacturer's instructions with the following modifications. Deoxyribonucleotides were present at the following concentrations: dA, dG, and dC at 500 µM each, dT at 100 µM and either Cy3-dUTP or Cy5-dUTP (Amersham) at 100 µM. cDNA synthesis reactions were carried out at 42-44° C for 90 minutes, after which RNA was degraded by the addition of 2 units of RNase H, and the cDNA products were purified by two successive rounds of centrifugation dialysis using MICROCON-30 microconcentrators (Amicon) according to the manufacturer's recommendations.

Double-stranded DNA polynucleotides corresponding in sequence to each ORF in the *S. cerevisiae* genome encoding a polypeptide greater than 99 amino acids (based on the published yeast genomic sequence, *e.g.*, Goffeau *et al.*, 1996, *Science* 274:546-567) are made by polymerase chain reaction (PCR) amplification of yeast genomic DNA. Two PCR primers are chosen internal to each of the ORFs according to two criteria: (i) the amplified fragments are 300-800 bp and (ii) none of the fragments have a section of more than 10 consecutive nucleotides of sequence in common. Computer programs are used to aid in the design of the PCR primers. Amplification is carried out in 96 well microtitre plates. The

5 resulting DNA fragments are printed onto glass microscope slides using the method of Shalon *et al.*, 1996, *Genome Research* 6:639-645.

10 Fluorescently-labeled cDNAs (2-6 µg) are resuspended in 4 X SSC plus 1 µg/µl tRNA as carrier and filtered using 0.45 µM filters (Millipore, Bedford, MA). SDS is added
5 to 0.3%, prior to heating to 100° C for 2 minutes. Probes are cooled and immediately hybridized to the microarrays produced as described in Example 6.2, for 4 hours at 65° C. Non-hybridized probe is removed by washing in 1 X SSC plus 0.1% SDS at ambient
15 temperature for 1-2 minutes. Microarrays are scanned with a fluorescence laser-scanning device as previously described (Schena *et al.*, 1995, *Science* 270:467-470; Schena *et al.*,
10 1995, *Proc. Natl. Acad. Sci. USA* 93:10539-11286) and the results (including the positions of perturbations) are recorded.

20 *Perturbations:* This example involved 18 experiments including different drug treatments and genetic mutations related to yeast *S. cerevisiae* biochemical pathway homologous to immunosuppression in human. Two drugs, FK506 and Cyclosporin were used at the
15 concentrations of 50 µg/ml or 1 µg/ml in combination with various gene deletions. Genes CNA1 and CNA2 encode the catalytic subunits of calcineurin. Cardenas *et al.*, 1994, *Yeast*
25 as model T cells, in *Perspectives in Drug Discovery and Design*, 2:103-126. The 18 different experiment conditions are listed in Table 1:

30 20

35 25

40 30

45 35

50 40

Table 1. Experimental Conditions in 18 Experiments

Experiment No.	Experimental conditions/Perturbations
1	+/- FK 506 (50 µg/ml)
2	+/- FK 506 (1 µg/ml)
3	-CPH1 +/- FK 506 (50 µg/ml)
4	-CPH1 +/- FK 506 (1 µg/ml)
5	-FPR +/- FK 506 (50 µg/ml)
6	-FPR +/- FK 506 (1 µg/ml)
7	-CNA1, CNA2 +/- FK 506 (50 µg/ml)
8	-CNA1, CNA2 +/- FK 506 (1 µg/ml)
9	-GCN4 +/- FK 506 (50 µg/ml)
10	-CNA1, CNA2, FPR +/- FK 506 (50 µg/ml)
11	-CNA1, CNA2, FPR +/- FK 506 (1 µg/ml)
12	-GCN4 +/- Cyclosporin A (50 µg/ml)
13	-FPR +/- Cyclosporin A (50 µg/ml)
14	+/- Cyclosporin A (50 µg/ml)
15	-CNA1, CNA2, CPH1 +/- Cyclosporin A (50 µg/ml)
16	-CNA1, CNA2 +/- Cyclosporin A (50 µg/ml)
17	-CPH1 +/- Cyclosporin A (50 µg/ml)
18	-/+CNA1, CNA2

Cluster analysis: The set of more than 6000 measured mRNA levels was first reduced to 48 by selecting only those genes which had a response amplitude of at least a factor of 4 in at least one of the 18 experiments. The initial selection greatly reduced the effect of measurement errors, which dominated the small responses of most genes in most experiments.

Clustering using the hclust routine was performed on the resulting data table 18 (experiments) x 48 (genes). The code 'hclust' was run using S-plus 4.0 on Windows NT workstation. The distance was $1 - r$, where the r is the correlation coefficient (normalized dot product). Statistical significance of each branch node was computed using the Monte Carlo procedure described previously herein. One hundred realizations of permuted data were clustered to derive an empirical improvement (in compactness) score for each

bifurcation. The score for the unpermuted data is then expressed in standard deviations and values are indicated on the tree of FIG. 6.

6.1.2. RESULTS AND DISCUSSION

FIG. 6 shows the clustering tree derived from 'hclust' algorithm operating on the 18x48 data table. The 48 genes were clustered into various branches. The vertical coordinate at the horizontal connector joining two branches indicates the distance between branches. Typical values are in the range of 0.2-0.4 where 0 is perfect correlation and 1 is zero correlation. The number at the branch is the statistical significance. Numbers greater than about 2 indicate that the branching is significant at the 95% confidence level.

The horizontal line of FIG. 6 is the cut off level for defining genesets. This level is arbitrarily set. Those branches with two or fewer members were ignored for further analysis. Three genesets with three or more members were defined at this cut off level. The significance values (in standard deviations) shown at the branch notes were derived as described, and show that the three branches are truly distinct. The clusters correspond to the pathways involving the calcineurin protein, the PDR gene and the Gcn4 transcription factor, which indicates that cluster analysis is capable of producing genesets that have corresponding genetic regulation pathways. See, Marton *et al.*, Drug Target validation and identification of secondary drug target effects using DNA microarrays, *Nature Medicine* 4:1293-1301.

6.2. EXAMPLE 2: ENHANCING DETECTION OF RESPONSE PATTERN USING GENESET AVERAGE RESPONSE

This example illustrates enhanced detection of a particular response pattern by geneset averaging.

Geneset number 3 in the clustering analysis result of FIG. 6 involves genes regulated by the Gcn4 transcription factor. This was verified via the literature and via multiple sequence alignment analysis of the regulatory regions 5' to the individual genes (Stormo and Hartzell, 1989, Identifying protein binding sites from unaligned DNA fragments, *Proc Natl Acad Sci* 86:1183-1187; Hertz and Stormo, 1995, Identification of consensus patterns in unaligned DNA and protein sequences: a large-deviation statistical basis for penalizing gaps, *Proc of 3rd Intl Conf on Bioinformatics and Genome Research*, Lim and Cantor, eds., World Scientific Publishing Co., Ltd. Singapore, pp. 201-216). Twenty of 32 genes in geneset 3 had a common promoter sequence appropriate to Gcn4. These 20 were used to define a geneset. Response profiles to a titration series of the drug FK506, which is known to hit this pathway at higher concentrations, were projected onto this geneset. The resulting projected

response is denoted 'Geneset' in Table 2, where the responses (in standard deviations of Log10(Expression Ratio)) of the individual genes are also shown. NaN means data not available. The 'Geneset' response becomes very significant (>3 sigma) at 1.6 µg/ml, and is much more significant than the individual gene responses at this and higher concentrations.

Table 2. Responses of Individual Genes and The Geneset Average Responses

		Concentration (µg/ml)					
		0.1	0.31	1.6	7.5	16	50
	Gene						
10	YBR047W	0.0781	0.1553	0.2806	1.1596	3.3107	4.248
	YER024W	0.1985	-0.0419	0.4868	1.1526	4.6342	5.8934
20	ARG5,6	0.1162	0.2722	1.1844	2.7433	6.0457	5.2406
	YGL117W	0.6309	0.6768	1.6276	2.699	4.9827	5.9066
	YGL184C	0.0654	-0.0207	-0.0731	-0.4586	2.7166	5.3106
25	ARG4	0.3585	0.3508	1.6674	3.2973	4.5135	5.8858
	YHR029C	-0.031	0.2438	0.4421	2.3813	5.0446	5.5781
	HIS5	0.0292	0.2175	0.9802	2.8414	6.0052	4.9557
30	CPA2	NaN	NaN	1.2429	NaN	4.1093	4.0958
	SNO1	-0.2899	0.0244	-0.4772	2.538	5.8877	5.5665
	SNZ1	-0.7223	0.0244	-0.4772	2.538	5.8877	5.5665
35	YMR195W	0.7615	0.3323	1.6021	0.8879	4.0983	4.6141
	NCE3	0.0371	0.1668	1.2896	1.569	5.5819	3.3928
25	ARG1	0.2083	0.3436	3.1765	4.2215	4.711	5.7996
	HIS3	-0.3719	0.1282	0.71	1.8024	4.6461	5.2637
40	SSU1	0.6257	0.6655	0.2883	0.5059	4.6461	3.5782
	MET16	0.0225	-0.6269	-0.1885	0.1621	3.3857	4.855
30	ECM13	0.1269	0.2197	0.5226	2.5343	4.8689	3.1882
45	ARO3	NaN	-0.1371	0.2684	0.6059	4.0553	5.7035
	PCL5	0.1418	0.2767	0.4127	2.2898	5.4688	5.2339
35	Geneset	0.1728	0.6753	3.3045	7.8209	19.9913	21.3315
50	Average						

6.3. EXAMPLE 3: IMPROVED CLASSIFICATION OF DRUG ACTIVITY

The 18-experiment data set mentioned in Example 1, *supra*, was combined with an additional 16 experiments using a variety of perturbations including immunosuppressive drugs FK506 and Cyclosporin A, and mutations in genes relevant to the activity of those drugs; and drugs unrelated to immunosuppression -- hydroxyurea, 3-Aminotriazole, and methotrexate. The experimental conditions are listed in Table 3:

Table 3. Additional 16 Experiments

Experiment No.	Experimental conditions/Perturbations
1	3-Aminotriazole (0.01 mM)
2	3-Aminotriazole (1 mM)
3	3-Aminotriazole (10 mM)
4	3-Aminotriazole (100 mM)
5	Hydroxyurea (1.6 mM)
6	Hydroxyurea (3.1 mM)
7	Hydroxyurea (6.2 mM)
8	Hydroxyurea (12.5 mM)
9	Hydroxyurea (25 mM)
10	Hydroxyurea (50 mM)
11	Methotrexate (3.1 μ M)
12	Methotrexate (6 μ M)
13	Methotrexate (25 μ M)
14	Methotrexate (50 μ M)
15	Methotrexate (100 μ M)
16	Methotrexate (200 μ M)

A cluster analysis was performed with the combined data set. A first down selection of genes was done by requiring the genes to have a significant response in 4 or more of the 34 experiments, where this threshold was defined precisely as greater than twofold up- or down-regulation, and a confidence level of 99%, or better. This selection yielded 194 genes. Less stringent thresholds would yield more genes and higher incidence of measurement errors contaminating the data and confusing the biological identifications of the genesets; however, the final results are not very sensitive to this threshold.

5 The 'hclust' procedure of S-Plus was used, giving the clustering tree shown in FIG. 7. There are 16 genesets at the cut level $D = 0.4$ shown in FIG. 7. Of these 16, 7 consist of two genes or less. Discarding these small clusters leaves 9 major clusters marked as shown in FIG. 7 with numbers 1-9. All the resulting bifurcations above the cut level are significant (more than two sigma – see numbers at each node), so the clusters are truly distinct.

10 It is noteworthy that genesets defined by the immunosuppressive drug pathways are again identified here even though non-immunosuppressive drug response data are combined in the analysis.

15 Geneset 2 contains the calcineurin dependent genes from Geneset 1 of FIG. 6, while Geneset 4 contains the Gcn4-dependent genes from Geneset 3 of FIG. 6.

20 The response to FK506 at 16 $\mu\text{g/ml}$ was obtained and the response profile was used as "unknown" profile. The response profile was projected into the genesets defined using the cluster analysis of the 34 experiments. The 34 profiles from the individual experiments from the clustering set also were projected onto the basis.

25 The projected profile for FK506 at 16 $\mu\text{g/ml}$ was compared with each of the 34 projected profiles from the clustering set. Five of these comparisons are illustrated in FIGs 8A–8E, and will be discussed in more detail below.

30 The correlation between the projected profile of the unknown, and the projected profile of each of the 34 training experiments was calculated using the equation 10 (Section 5.4.2, *supra*) and is displayed as circles (-O-) in FIG. 9.

35 Also displayed for comparison are the correlation coefficients computed without projection (-Δ-), and without projection but with restriction to those genes that were up- or down-regulated at the 95% confidence level, and by at least a factor of two, in one or the other of the two profiles (-◇-).

40 In general, the projected correlation coefficients track the unprojected ones, and show larger values. The larger values are a consequence of the averaging out of measurement errors which occurs during projection onto the genesets. These individual measurement errors tend to bias the unprojected correlation coefficients low, and this bias is reduced by the projection operation.

45 The correlation coefficient of the projected profiles tends to have large errors when the original profile response was very weak and noise-dominated. Such is the case at some of the lower concentrations of drug treatment including Experiments 1,2,7,8. In Experiment 2, for example, there is a projected correlation coefficient of negative 0.45, where the unprojected correlations are close to zero. This is a consequence of noise dominance of the correlation coefficient. FIG. 8A shows that treatment with HU at 3.1 mM (gray bars) has a very weak projected profile.

FIG. 8B gives the elements of the projected profiles for the comparison of FK506 at 16 µg/ml (the unknown) with Experiment No. 25 in FIG. 9, FK506 at 50 µg/ml. The projected profiles are highly consistent with the very high correlation values in FIG. 9. The largest response is in Geneset 7, which corresponds biologically to an amino acid starvation response evidently triggered at large concentrations of the drug. The response in Geneset 5 is mediated via the primary target of the drug, the calcineurin protein. This response is still present at lower concentrations of the drug (FIG. 8C, gray bars, FK506 at 1 µg/ml), while the response in Geneset 7 and other Genesets is greatly reduced. This biological interpretation is an immediate aid in classification of drug activity. It can be concluded that the higher concentration of the drug has triggered secondary, (probably undesirable), pathways. One of the primary mediators of these pathways turns out to be the transcription factor Gcn4, as shown by the grey profile in FIG. 8D from Experiment 34 listed in FIG. 8A. Here, the activity in Genesets 2,3, and 7 is removed by the deletion of the GCN4 gene.

However, blind classification using the projected profiles also is improved. Note that the projected correlation coefficients show that the next-nearest neighbor to the unknown is the experiment two rows above the best match, '-cph +/- FK506 at 50 µg/ml'. This is treatment with the drug of cells genetically deleted for the gene CPH1. This gene is not essential to the activity of FK506, and should not greatly change the response. Thus the projected profile correctly shows a high similarity with the unknown, FK506 at 16 µg/ml. The unprojected correlation coefficients, however, declare the experiment six rows above the best match, '-cna +/- FK506 at 50 µg/ml', to be the second best match. This experiment involves treatment with the drug of cells genetically deleted for the primary target, calcineurin. In this case, the response to Geneset 5, mediated by calcineurin, has disappeared (see FIG. 8E) while the other responses remain. This important biological difference is reflected in the projected elements of FIG. 8E and in the projected correlation coefficients, but not in the unprojected correlation coefficients. Thus conclusions about biological similarity would be more reliable in this case based on the projected correlation coefficients using the method of the invention than based on unprojected methods.

6.4 EXPERIMENT 4: IMPROVED CLASSIFICATION OF BIOLOGICAL RESPONSE PROFILES

The 34-experiment data set described in Example 3 (Section 6.3, *supra*) was also analyzed by two-dimensional cluster analysis. In particular, cluster analysis was first performed with the data set to identify genesets as described in Example 3, *supra*. Next, the 'hclust' procedure of S-Plus was used again, this time to organize the biological response profiles according to the similarity of the biological response.

5 The results of this analysis are illustrated in Fig. 16. Fig. 16A shows a gray scale
display of the plurality of reduced genetic transcripts (horizontal axis) measured in the 34-
experiments (vertical axis). Thus, each row in Fig. 16A indicates the response of genetic
10 transcripts to a particular perturbation (e.g., exposure to a particular drug). The gray scale
5 represents the logarithm of measured expression ratio as shown in the gray scale bar on the
top of Fig. 16. Specifically, black denotes up regulation of a transcript (+1), whereas white
denotes down regulation (-1), and the middle gray scale (0) denotes no change in expression.
15 Fig. 16B illustrates co-regulation tree of genetic transcriptions (i.e., the columns in Fig. 16A)
into genesets described in Example 3, *supra*. The column index order represented in this co-
10 regulation tree was then used to re-order the column in Fig. 16A to generate the display
shown in Fig. 16C. The same clustering algorithm was then applied to the row in Fig. 16C
20 (i.e., to the response profiles), and the row index was similarly re-ordered to generate Fig.
16D.

Comparing Figs. 16A and 16D, large structures are readily evident after the
15 reordering. Not only can genesets be readily identified from vertical striping in Fig. 16D, but
sets of experiments associated with the activation of particular genesets are also identified
25 from horizontal striping in Fig. 16D. Fig. 17 gives a more detailed view of Fig. 16D, and
details the experiment assignments and some of the geneset assignments in the reo-ordered
form of Fig. 16D. For example, the 'CNA' vertical stripe indicated in Fig. 17 is the
30 calcineurin-dependent geneset, which is affected (i.e., transcription repressed) by all the
experiments involving immunosuppressive drugs in cells except those where the intermediate
targets of the drug, or calcineurin itself, have been removed with mutations. The experiments
contributing to the large horizontal stripe all activate sets of genesets which are mostly Gcn4-
35 dependent. This is particular evident when these experiments are compared with the top two
25 rows of Fig. 17 which comprise experiments wherein Gcn4 has been deleted.

6.5. EXAMPLE 5: PROJECTING OUT PROFILE ARTIFACTS

40 Two sets of experiments were performed according to the reverse transcription
procedure described in Example 1 (Section 6.1.1 *supra*) where the effect of deletion of the
30 YJL107c gene was measured. In one of the two experiments, RNA concentration in the
procedure was (intentionally) poorly controlled, thereby generating response profile data that
45 was contaminated by artifacts. The correlation between the two profiles, determined by
Equation 7, is shown in Fig. 18. Asterix symbols (*) indicate those transcripts which were
up- or down-regulated in either of the two experiments at a confidence level of 90% or more.
35 The correlation coefficient between the two experiments is 0.82.

5 An artifact template, characterizing the effect of poor control of RNA concentration in
a reverse transcription procedure, was generated by measuring transcript levels in *S.*
cerevisiae wherein the RNA concentration was intentionally varied. Thus, a response profile
10 was obtained wherein the "perturbation" was, in fact, the variation of RNA concentration in
5 the reverse transcription procedure. This template is plotted in Fig. 19 as gene expression
ratio vs. mean expression level. Those transcripts which were up- or -down regulated at the
90% confidence level were labeled with their names and have one-sigma error bars.

15 The response profile corresponding to the contaminated YJL107c deletion experiment
was cleaned using this artifact template. Specifically, best scaling coefficients were
10 determined by least squares minimization of Equation 16, and a "cleaned" response profile
was generated with these coefficients according to Equation 17. The correlation between the
"cleaned" YJL107c deletion experiment and the corresponding "uncontaminated" experiment
20 is shown in Fig. 20. The correlation is improved to 0.87. IN the absence of significant
artifacts, other sources of random measurement error commonly limit the correlation between
15 nominally repeated measurements of profiles to about 0.90. Thus, the improvement from
0.82 to 0.87 represents nearly the maximum amount of improvement that is realistically
25 possible with any artifact removal technique.

7. REFERENCES CITED

20 All references cited herein are incorporated herein by reference in their entirety and
for all purposes to the same extent as if each individual publication or patent or patent
30 application was specifically and individually indicated to be incorporated by reference in its
entirety for all purposes.

35 Many modifications and variations of this invention can be made without departing
25 from its spirit and scope, as will be apparent to those skilled in the art. The specific
embodiments described herein are offered by way of example only, and the invention is to be
limited only by the terms of the appended claims, along with the full scope of equivalents to
40 which such claims are entitled.

30

35

Claims

5

10

15

20

25

30

35

40

45

50

55

5 WHAT IS CLAIMED IS:

- 10 1. A method for analyzing a biological sample comprising converting a first profile of a
5 plurality of measurements of cellular constituents in said biological sample into a projected
 profile containing a plurality of cellular constituent set values according to a definition of co-
 varying basis cellular constituent sets, wherein said definition is based upon the co-variation
 of said cellular constituents under a plurality of different perturbations, and wherein said
15 converting comprises projecting said first profile onto said basis cellular constituent sets.
- 20 2. The method of claim 1, wherein the plurality of different perturbations comprises at
 least five different perturbations.
- 25 3. The method of claim 2, wherein the plurality of different perturbations comprises
 more than ten different perturbations.
- 30 4. The method of claim 3, wherein the plurality of different perturbations comprises
 more than 50 different perturbations.
- 35 5. The method of claim 4, wherein the plurality of different perturbations comprises
 more than 100 different perturbations.
- 40 6. The method of claim 1 further comprising the step of indicating the state of said
 biological sample with said projected profile.
- 45 7. The method of claim 1 further comprising the steps of comparing said projected
 profile with a reference projected profile, and indicating similarity or difference between said
 projected profile and said reference profile.
- 50 8. The method of claim 1, wherein said definition is based upon the co-variation of said
 cellular constituents under a plurality of different perturbations.
- 55 9. The method of claim 8 wherein said definition is defined by a similarity tree derived
 by a cluster analysis of said cellular constituents under said plurality of perturbations.
10. The method of claim 9 wherein said cellular constituent sets are defined as branches
 of said similarity tree.

11. The method of claim 10 wherein said branches are selected by applying a cutting level across said tree, wherein said cutting level is determined by expected number of biological pathways represented by said cellular constituents.

12. The method of claim 10 wherein distinction among said branches achieves a statistical significance at 95% confidence level.

13. The method of claim 12 wherein said statistical significance is evaluated with a test using Monte Carlo randomization of an index of said perturbations.

14. The method of claim 13 wherein the test using Monte Carlo randomization comprises:

- (a) determining an actual fractional improvement in cluster analysis of said cellular constituents;
- (b) generating permuted cellular constituents by means of Monte Carlo randomization of each perturbation for each cellular constituent;
- (c) performing cluster analysis on the permuted cellular constituents;
- (d) determining the fractional improvements in the cluster analysis of the permuted cellular constituents; and
- (e) repeating said steps of generating permuted cellular constituents and performing cluster analysis on the permuted cellular constituents so that a distribution of fractional improvements is obtained,

wherein the statistical significance is determined by comparing the actual fractional improvement to the distribution of fractional improvements.

15. The method of claim 12 wherein said statistical significance is evaluated with a test using Monte Carlo randomization of a time index of a biological response to one or more perturbations.

16. The method of claim 10, 11, or 12, wherein said defined cellular constituent sets are refined based upon biological relationships among said cellular constituents.

17. The method of claim 1 wherein said definition is:

$$V = \begin{bmatrix} V_1^{(1)} & \cdot & V_1^{(n)} \\ \cdot & \cdot & \cdot \\ V_k^{(1)} & \cdot & V_k^{(n)} \end{bmatrix}$$

wherein $V_k^{(n)}$ is the contribution of cellular constituent k to cellular constituent set n.

18. The method of claim 17 wherein said step of converting comprises the execution of the operation:

$$P = [P_1, \dots, P_i, \dots, P_n] = p \bullet V$$

wherein P_i is cellular constituent set value i and vector p is a profile of cellular constituents.

19. The method of claim 1 wherein each of said cellular constituent set values is the average value of the level of said cellular constituents within a corresponding cellular constituent set.

20. The method of claim 1 wherein each of said cellular constituent set value is a weighted average of the level of said cellular constituents within a corresponding cellular constituent set.

21. The method of claim 1 wherein said plurality of measurements is normalized to a unity vector size.

22. The method of claim 1 wherein said measurements of cellular constituents are measurements of responses of said biological sample to a perturbation.

23. A method for analyzing a biological sample comprising:

- (a) converting a first profile of a plurality of measurements of cellular constituents in said biological sample into a projected profile containing a plurality of cellular constituent set values according to a definition of co-varying basis cellular constituent sets, wherein said converting comprises projecting said first profile onto said basis cellular constituent sets;
- (b) comparing said projected profile with a reference profile; and
- (c) indicating similarity or difference between said projected profile and said reference profile.

24. The method of claim 23 wherein said definition is derived from the co-regulation of said cellular constituents.

25. The method of claim 23 wherein said definition is based upon the co-variation of said cellular constituents under a plurality of different perturbations.

26. The method of claim 23 wherein said definition is:

$$V = \begin{bmatrix} V_1^{(1)} & \cdot & V_1^{(n)} \\ \cdot & \cdot & \cdot \\ V_k^{(1)} & \cdot & V_k^{(n)} \end{bmatrix}$$

wherein $V_k^{(n)}$ is the contribution of cellular constituent k to cellular constituent set n.

27. The method of claim 26 wherein said step of converting comprises the execution of the operation:

$$P = [P_1, \dots, P_i, \dots, P_n] = p \bullet V$$

wherein P_i is cellular constituent set value i and vector p is a profile of cellular constituents.

28. The method of claim 23 wherein each of said cellular constituent set values is the average value of the level of said cellular constituents within a corresponding cellular constituent set.

29. The method of claim 23 wherein each of said cellular constituent set value is a weighted average of the level of said cellular constituents within a corresponding cellular constituent set.

30. The method of claim 23 wherein said plurality of measurements is normalized to a unity vector size.

31. The method of claim 23 wherein said measurements of cellular constituents are measurements of responses of said biological sample to a perturbation.

32. A method for analyzing a biological sample comprising converting a first profile of a plurality of measurements of cellular constituents in said biological sample into a projected profile containing a plurality of cellular constituent set values according to a definition of co-varying basis cellular constituent sets, wherein said definition is provided by the expression

$$V = \begin{bmatrix} V_1^{(1)} & \dots & V_1^{(n)} \\ \vdots & \ddots & \vdots \\ V_k^{(1)} & \dots & V_k^{(n)} \end{bmatrix}$$

in which $V_k^{(n)}$ is the contribution of cellular constituent k to cellular constituent set n, and wherein said converting comprises projecting said first profile onto said basis cellular constituent sets.

33. The method of claim 32 wherein said step of converting comprises the execution of the operation:

$$P = [P_1, \dots, P_i, \dots, P_n] = p \bullet V$$

wherein P_i is cellular constituent set value i and vector p is a profile of cellular constituents.

34. A method for analyzing a biological sample comprising converting a first profile of a plurality of measurements of cellular constituents in said biological sample into a projected profile containing a plurality of cellular constituent set values according to a definition of co-varying basis cellular constituent sets, each of said cellular constituent set values being a weighted average of the level of said cellular constituent within a corresponding cellular constituent set, wherein said converting comprises projecting said first profile onto said basis cellular constituent sets.

35. A method for analyzing a biological sample comprising converting a first profile of a plurality of measurement of cellular constituents in a biological sample into a projected profile containing a plurality of cellular constituent set values according to a definition of co-varying basis cellular constituent sets, said plurality of measurements being normalized to a unity vector size, wherein said converting comprises projecting said first profile onto said basis cellular constituent sets.

36. A method of grouping biological response profiles according to the similarity of the responses, said method comprising defining similar response profile sets based upon the similarity of a plurality of measured cellular constituents in said response profiles.

37. The method of claim 36, further comprising the step of forming a clustering tree derived by a cluster analysis of similarity of the plurality of measured cellular constituents in said response profiles.

5 38. The method of claim 37, wherein groups of said biological response profiles are defined as branches of said clustering tree.

10 39. The method of claim 36, further comprising determining a statistical significance of
5 the groups of biological response profiles.

15 40. The method of claim 39, wherein the statistical significance of the groups of biological response profiles is determined by means of an objective statistical test.

10 41. The method of claim 40, wherein the objective statistical test comprises:
20 (a) determining an actual fractional improvement in cluster analysis of the biological response profiles;
(b) generating permuted response profiles by means of Monte Carlo randomization of each cellular constituent for each response profile;
15 (c) performing cluster analysis on the permuted response profiles;
25 (d) determining the fractional improvement in the cluster analysis of the permuted response profiles; and
(e) repeating said steps of generating permuted response profiles and performing cluster analysis on the permuted response profiles so that a distribution of
30 fractional improvements is obtained,
wherein the statistical significance is determined by comparing the actual fractional improvement to the distribution of fractional improvements.

35 42. A method for analyzing a biological sample comprising:

- 25 (a) grouping cellular constituents from the biological sample into sets of cellular constituents that co-vary in biological profiles obtained from the biological sample; and
40 (b) grouping the biological profiles obtained from the biological sample into sets of biological profiles that effect similar cellular constituents.

30 43. The method of claim 42, wherein one or more cellular constituents associated with a particular biological effect are identified from said sets of cellular constituents.
45

44. The method of claim 42, wherein one or more biological profiles associated with a
35 particular biological effect are identified from said sets of biological profiles.

5 45. The method of claim 43 or 44, wherein the particular biological effect is a biological pathway.

10 46. The method of claim 43 or 44, wherein the particular biological effect is a disease or
5 disease state.

15 47. The method of claim 43 or 44, wherein the particular biological effect is the effect of treatment with one or more drugs.

20 48. The method of claim 43, wherein the cellular constituents from the biological sample comprise a plurality of genes, and one or more genes associated with a particular biological effect are identified.

25 49. The method of claim 46, wherein the one or more genes identified comprise known
15 genes.

50 50. The method of claim 46, wherein the one or more genes identified comprise previously unknown genes.

30 51. The method of claim 42, wherein one or more perturbations associated with a particular biological effect are identified from said sets of biological profiles.

35 52. The method of claim 49, wherein the one or more perturbations comprise a drug or a drug candidate.

25 53. The method of claim 50, wherein the one or more perturbations comprise a genetic mutation.

40 54. The method of claim 50 wherein the drug or drug candidate is a known drug or drug
30 candidate.

45 55. The method of claim 51, wherein the genetic mutation is a known genetic mutation.

50 56. The method of claim 50, wherein the drug or drug candidate is a previously unknown
35 drug or drug candidate.

5 57. The method of claim 51, wherein the genetic mutation is a previously unknown genetic mutation.

10 58. A method for analyzing an N-dimensional array of data, N being a positive integer,
5 wherein each element of the N-dimensional array of data has N indices, said method comprising grouping each index into sets of data that co-vary within the N-dimensional array of data.

15 59. The method of claim 56, wherein each of said sets is defined by a similarity tree
10 derived by a cluster analysis of each of said indices.

20 60. A method for removing one or more artifacts from a measured biological profile comprising a plurality of measurements of cellular constituents, said method comprising subtracting one or more artifact patterns from the measured biological profile, wherein each
15 of said one or more artifact patterns corresponds to a particular artifact.

25 61. The method of claim 58, wherein the each of the one or more artifact patterns is provided by knowledge of the genes and relative amplitudes of responses associated with particular artifact to which each of the one or more artifact patterns corresponds.

30 62. The method of claim 58, wherein each of the one or more artifact patterns is provided by experiments with perturbations of suspected causative variables of the particular artifact to which each of the one or more artifact patterns corresponds.

35 63. The method of claim 58, wherein each of the one or more artifact patterns is provided by a cluster analysis of control biological profiles, the control biological profiles comprising a plurality of measurements of cellular constituents in experiments wherein the artifact to which each of the one or more artifact pattern corresponds arises.

40 64. The method of claim 58, wherein of the one or more artifact patterns are scaled by scaling coefficients, each of the one or more artifact patterns having a particular scaling coefficient.

45 65. The method of claim 62, wherein the scaling coefficients are determined by a method
35 comprising determining the value of each particular scaling coefficient which minimizes the

5 value of an objective function of the difference between the measured profile and the sum of the one or more scaled artifact patterns.

10 66. The method of claim 63, wherein the objective function is a least squares minimization.

15 67. The method of claim 58, wherein each of the one or more artifact patterns is selected from a library of artifact signatures, said artifact signatures corresponding to levels of severity of each the one or more artifacts.

20 68. The method of claim 65, wherein the artifact signatures are selected by a method comprising determining the artifact signatures which minimize the values of an objective function of the difference between the measured profile and the sum of the one or more artifact signatures.

25 69. The method of claim 1, wherein the plurality of different perturbations comprises a plurality of graded levels of exposure to a particular perturbation.

30 70. The method of claim 67, wherein the particular perturbation is a drug or drug candidate.

35 71. The method of claim 1, wherein said definition is based upon the co-variation of the cellular constituents over a period of time.

40 72. An array of polynucleotide probes, said array comprising a support with at least one surface and a plurality of different polynucleotide probes, wherein each different polynucleotide probe:

- 45 (a) is attached to the surface of the support at a different location on said surface;
(b) comprises a different nucleotide sequence; and

50 (c) hybridizes to an expression product of a particular gene within a single geneset of a plurality of genesets, in which

- 55 (i) said plurality of genesets is provided by a method comprising grouping genes from a biological sample into sets of genes that co-vary in biological profiles obtained from the biological sample, and
(ii) the number of different polynucleotide probes for each geneset that hybridize to an expression product of a different particular gene

5 within said geneset is less than the total number of genes in the
 geneset.

10 73. The array of claim 72 wherein the plurality of different polynucleotide probes
5 hybridizes to expression products of genes from between 50 and 1,000 different genesets.

15 74. The array of claim 73 wherein the plurality of different polynucleotide probes
 hybridizes to expression products of genes from between 100 to 500 different genesets.

20 75. The array of claim 74 wherein the plurality of different polynucleotide probes
 hybridizes to expression products of genes from between 100 to 200 different genesets.

25 76. The array of claim 72 wherein each particular gene is selected from a different
 geneset.

30 77. The array of claim 72 wherein the plurality of different polynucleotide probes
 hybridizes to expression products of no more than 10 particular genes from any one geneset.

35 20

40 25

45 30

50 35

1/27




FIG.1

2/27





FIG.2

FIG.3



4/27




FIG.4A

5/27

EARLY




FIG. 4B

ADAPTIVE





FIG. 4C

6/27



* GIVEN LOW WEIGHT IN CLUSTERING OPERATION

FIG.4D

7/27





FIG. 5

SUBSTITUTE SHEET (RULE 26)

8/27



9/27




FIG.7

10/27




FIG.8A

11/27




FIG.8B

12/27




FIG.8C

13/27




FIG.8D

14/27




FIG.8E

15/27




FIG.9

16/27




FIG.10





FIG. 11



19/27




FIG.13

20/27




FIG.14

21/27






FIG.15







FIG. 16C

By
Experiment.
To
FIG. 16D




FIG. 16D

SUBSTITUTE SHEET (RULE 26)

24/27




FIG.17

SUBSTITUTE SHEET (RULE 26)

25/27





FIG.18

SLIDES: 5655c02 -5688c01 5640c01 -5630c01 5240c01 -5641c01



27/27




FIG.20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25025

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68

US CL : 435/6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, STN files MEDLINE, BIOSIS, LIFESCI, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 5,965,352 A (STOUGHTON ET AL) 12 October 1999(21.10.99), col. 3, line 50 through col. 6 line 60.	1-77

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T
"A" document defining the general state of the art which is not considered to be of particular relevance	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" documents which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"Z" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 DECEMBER 1999

Date of mailing of the international search report

04 APR 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANELL TAYLOR

Telephone No. (703) 308-0196